



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

The human immune response to respiratory syncytial virus infection

Citation for published version:

Russell, C, Unger, SA, Walton, M & Schwarze, J 2017, 'The human immune response to respiratory syncytial virus infection', *Clinical Microbiology Reviews*, vol. 30, no. 2, pp. 481-502.
<https://doi.org/10.1128/CMR.00090-16>, <https://doi.org/10.1128/CMR.00090-16>

Digital Object Identifier (DOI):

[10.1128/CMR.00090-16](https://doi.org/10.1128/CMR.00090-16)
[10.1128/CMR.00090-16](https://doi.org/10.1128/CMR.00090-16)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Clinical Microbiology Reviews

Publisher Rights Statement:

This is the author's peer reviewed manuscript as accepted for publishing.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 The human immune response to respiratory syncytial virus infection

2

3

4 Clark D Russell,^{a*} Stefan A Unger,^{b*} Marc Walton,^a Jürgen Schwarze^{a,b,#}

5

6 *Contributed equally

7

8 MRC Centre for Inflammation Research, Queen's Medical Research Institute, University of

9 Edinburgh, Edinburgh, UK^a; Department of Child Life and Health, University of Edinburgh,

10 Edinburgh, UK^b

11

12 Running Head: Human immune response to RSV infection

13

14 #Address correspondence to Professor Jürgen Schwarze, jurgen.schwarze@ed.ac.uk

15 C.D.R. and S.A.U. contributed equally to this work.

16

17	TABLE OF CONTENTS	
18	SUMMARY	p4
19	INTRODUCTION	p5
20	METHODS OF SYSTEMATIC LITERATURE REVIEW	p6
21	SYSTEMIC AND PULMONARY IMMUNE CELL RESPONSES TO RSV	
22	INFECTION	
23	Neutrophils	p7
24	Natural killer (NK) cells	p8
25	Dendritic cells (DC)	p8
26	Macrophages and Monocytes	p9
27	Eosinophils	p10
28	T-lymphocytes	p10
29	Defective T-cell responses	p13
30	Cellular Response in Term and Pre-term infants	p13
31	B-LYMPHOCYTE RESPONSES AND ANTIBODY PRODUCTION DURING RSV	
32	INFECTION	
33	Antibody Production and B-lymphocyte Stimulation	p14
34	Protective Effects of RSV-IgG and RSV-IgA	p15
35	Other Mechanisms of RSV-Specific Antibody Activity	p16
36	Immunoglobulin E	p17
37	Th1 AND Th2 RESPONSES TO RSV INFECTION	
38	Th1 Responses	p17
39	Systemic	p18
40	Respiratory tract	p18
41	Th2 Responses	p19

42	Systemic.....	p19
43	Respiratory tract.....	p20
44	Th1/Th2 Balance.....	p21
45	CHEMOKINES, CYTOKINES AND OTHER IMMUNE MOLECULES EXPRESSED	
46	DURING RSV INFECTION	
47	Overview.....	p22
48	Interleukin-8.....	p22
49	Interleukin-17A.....	p23
50	CC Chemokines.....	p23
51	Pattern Recognition Receptors (PRR).....	p24
52	Innate Interferons.....	p24
53	microRNA.....	p25
54	GLOBAL HOST TRANSCRIPTIONAL RESPONSE TO RSV INFECTION	
55	RELATIONSHIP BETWEEN MOLECULAR AND CELLULAR IMMUNE	
56	RESPONSES TO RSV AND PATHOPHYSIOLOGY	
57	RSV INFECTION AND SUBSEQUENT RESPIRATORY HEALTH	
58	KEY DIFFERENCES IN THE IMMUNE RESPONSE TO RSV BETWEEN ANIMAL	
59	MODELS AND HUMANS	
60	CONCLUSION	
61	ACKNOWLEDGEMENTS	
62	REFERENCES	
63	AUTHOR BIOGRAPHIES	
64	FIGURE LEGENDS	

66 **SUMMARY**

67

68 Respiratory syncytial virus (RSV) is an important aetiological agent of respiratory infections,
69 particularly in children. Much data regarding the immune response to RSV comes from
70 animal models and *in vitro* studies. Here, we provide a comprehensive description of the
71 human immune response to RSV infection, based on a systematic literature review of
72 research in infected humans.

73

74 There is an initial strong neutrophil response to RSV infection in humans, positively
75 correlated with disease severity and mediated by IL-8. Dendritic cells migrate to the lungs as
76 the primary antigen presenting cell. An initial systemic T-cell lymphopenia is followed by a
77 pulmonary CD8⁺ T-cell response, mediating viral clearance. Humoral immunity to re-
78 infection is incomplete but RSV-IgG and -IgA are protective. B-cell stimulating factors
79 derived from airway epithelium play a major role in protective antibody generation. IFN- γ
80 has a strongly protective role and a Th2-biased response may be deleterious. Other cytokines
81 (particularly IL-17A), chemokines (particularly CCL-5 and CCL-3) and local innate immune
82 factors (including cathelicidins and IFN- λ) contribute to pathogenesis.

83

84 In summary, neutrophilic inflammation is incriminated as a harmful response whereas CD8⁺
85 T-cells and IFN- γ have protective roles. These may represent important therapeutic targets to
86 modulate the immunopathogenesis of RSV infection.

87

88 INTRODUCTION

89

90 Respiratory syncytial virus (RSV) is an enveloped single-stranded RNA virus belonging to
91 the *Pneumoviridae* family of the *Mononegavirales* order. Infections occur worldwide, with
92 outbreaks in temperate climates occurring primarily during the winter months. RSV is an
93 important aetiological agent of respiratory infections, particularly in children, causing a
94 spectrum of illness encompassing upper respiratory tract infections (URTI) and lower
95 respiratory tract infections (LRTI), including pneumonia and bronchiolitis which are
96 associated with greater morbidity and mortality. Natural infection results in incomplete
97 immunity, permitting recurrent infection in childhood as well as infections in adults and the
98 elderly. Much data regarding the immune response to RSV comes from murine and other
99 animal models and *in vitro* human cell culture studies. While important for hypothesis
100 generation, these methodologies may not provide a completely accurate reflection of the
101 immune response during infection in humans. Here, we provide a comprehensive description
102 of the human immune response to RSV infection, based on a systematic literature review
103 exclusively of clinical, *ex vivo* and post mortem data from naturally and experimentally
104 infected humans.

105

106 In this review we consider the existing data describing the major cellular and humoral
107 components of the immune response to RSV, distinguishing events occurring systemically
108 from those occurring locally within the respiratory tract. First we describe the behaviour of
109 all major immune cell types, encompassing neutrophils, dendritic cells, monocytes,
110 macrophages, eosinophils and T-lymphocytes. Secondly, the anti-RSV antibody response and
111 its regulation is discussed. Next, the distinct Th1 and Th2 responses to RSV and the effect of
112 their balance on disease progression are considered. Several chemokines, cytokines and other

immune molecules have been demonstrated to be involved in the immune response and are reviewed. The global host transcriptional response is also discussed in the context of immune-related pathways. Certain key pathogen-host interactions described herein may represent targets for the development of novel therapeutics. For completeness, we summarise the association between RSV infection and subsequent asthma and also key differences between immune responses in humans and animals used in model systems of infection.

METHODS OF SYSTEMATIC LITERATURE REVIEW

We conducted a systematic literature review following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (PROSPERO registration number CRD42016047320). An electronic literature search of Medline, Embase and Web of Science was performed using the following search terms: ((RSV[Title] OR respiratory syncytial virus[Title])) AND (Immune response OR T-cell OR B-cell OR lymphocyte OR macrophage OR neutrophil OR monocyte OR natural killer cell OR dendritic cell OR immunoglobulin OR IgG OR IgA OR IgE OR cytokine OR chemokine OR interleukin OR interferon) AND (Human OR clinical OR experimental OR neonate OR infant OR children OR adult OR elderly)).

The last search was conducted on 16th May 2016. The results from the databases were merged and duplicates removed. The combined results of the electronic database search were assessed independently by two authors and discrepancies discussed and agreed upon according to the inclusion and exclusion criteria. Publications in all languages describing primary research in humans were included (clinical, *ex vivo*, post mortem). Editorials, reviews, commentaries and opinion pieces were excluded. Articles were limited to those

published after 1990. Additional articles of interest were identified from reviewing the bibliographies of relevant articles. The literature search resulted in 2541 publications after removal of duplicates and pre-1990 publications. Two authors reviewed titles and abstracts and identified 268 records that then underwent full text review. Of these, 166 met the inclusion criteria. A further 9 articles were identified through other sources including bibliographies of identified articles.

SYSTEMIC AND PULMONARY IMMUNE CELL RESPONSES TO RSV INFECTION

Neutrophils

RSV infection elicits a strong systemic and especially respiratory tract neutrophil response (1-4). Neutrophils are the predominant cell type in bronchoalveolar lavage (BAL) from the lungs of ventilated infants with severe RSV-bronchiolitis and those with milder infection (5). These cells are activated during the initial pathogenesis of RSV-LRTI, producing neutrophil elastase (6, 7) and expressing activation markers (CD11b, CD18 and CD54 [ICAM-1]) (8, 9). The peak neutrophil response coincides with maximum clinical severity and viral load, and by the time infants with severe infection are discharged from the intensive care unit (ICU) after ventilation, neutrophil counts in peripheral blood have normalised (10). Widespread neutrophil infiltration is seen in lung tissue from fatal cases of RSV-LRTI (3, 11).

During severe infection the virus interacts directly with neutrophils. Cells from peripheral blood and BAL express RSV proteins F, G, and N proportionately, implying stoichiometric expression thus intact intracellular virions (12). RSV genomic RNA and mRNA is also

present intracellularly (12, 13). This could be explained by phagocytosis of virions or replication of RSV within neutrophils. These RSV-containing neutrophils detected in the peripheral blood may have transmigrated from the lungs into the circulation.

Neutrophil apoptosis and neutrophil extracellular trap formation ('NETosis'; a unique form of neutrophil cell death) are active during infection. Proteins involved in apoptosis (Annexin V and the Fas death receptor CD95) are up-regulated in nasopharyngeal fluid and NETs are present in BAL from ventilated children (8, 14). NETs may prevent spread of infectious virions and comprise a web-like DNA backbone studded with histones and cytotoxic/antimicrobial proteins.

Natural Killer (NK) cells

RSV infection results in reduced total systemic NK cell counts albeit with an increase in an activated sub-set that lacks expression of CD94 (15, 16). Circulating NK cells have higher expression of the inhibitory leukocyte immunoglobulin-like receptor subfamily B member (LILRB1) suggesting they may contribute to regulation of inflammation during infection (17). Lower systemic total counts correlate with greater severity of infection and NK cells are sparse in lung tissue from fatal cases (3, 15, 18, 19). In contrast, there is accumulation of granzyme B-expressing NK cells in the respiratory tract of infants ventilated due to severe RSV-bronchiolitis (BAL and tracheal aspirate), possibly suggesting migration to the lungs (20, 21).

Dendritic Cells (DC)

Conventional (cDC) and plasmacytoid (pDC) DCs are mobilized from the circulation to the nasal mucosa early during infection with a further increase in DC counts during subsequent convalescence (22, 23). The RSV fusion protein is present within HLA-DR+ DCs in the nasal mucosa and the selective emigration of DCs, but not monocytes, highlights their likely role as the primary antigen presenting cell during RSV infection (23). Low numbers of blood pDCs have been associated with the development of RSV-bronchiolitis suggesting either increased emigration to the respiratory tract or an insufficient pDC response in severe RSV infection (24).

cDCs and pDCs have also been found in the lower airways of infants ventilated due to severe RSV-bronchiolitis where cDCs exhibit an activated pro-inflammatory phenotype (20). Circulating cDCs express the activation marker CD83 and the co-stimulatory molecule CD40. Concentrations of innate immune pro-inflammatory cytokines (IL-6, TNF- α , IL-8) and T-cell derived cytokines (IFN- γ , IL-13, IL-10, IL-2) in BAL correlate with cDC counts. In subsets of infants with severe RSV-bronchiolitis (pre-term infants and infants aged four months or more) pulmonary pDC counts are low compared to term born and younger infants, suggesting an inadequate antiviral response as a factor in severe RSV disease (20).

Macrophages and Monocytes

Alveolar macrophages obtained from BAL from RSV-infected infants and adult transplant recipients co-express RSV surface glycoproteins, HLA-DR molecules, IL-1 β and cytoplasmic TNF- α , suggesting a local immune-regulatory and antigen presenting role (25, 26). The cells appear to be infected productively, as viral replication from the cells can be confirmed *ex vivo* (25).

213

214 CD69⁺ monocytes are present in lung tissue from fatal cases of RSV infection (11). In the
215 peripheral blood, monocytes display reduced TLR8 expression and TNF- α production during
216 acute RSV-infection, which subsequently normalises in convalescence (27). In contrast,
217 circulating monocytes increase their expression of TLR4 in RSV infection (28).

218 **Eosinophils**

219

220 Eosinophils are activated during the acute phase of RSV-LRTI and may contribute to
221 recovery. Expression of the myeloid activation marker CD11b on circulating eosinophils
222 from infants with RSV-LRTI is increased, and inversely correlates with the required duration
223 of supplemental oxygen (29). In comparison to children hospitalised due to influenza virus or
224 adenovirus infection, those with RSV infection have higher systemic eosinophil counts
225 during recovery but not at presentation (30). Despite a lack of data demonstrating significant
226 eosinophil *recruitment* to the respiratory tract, there is evidence of eosinophil *activity* during
227 bronchiolitis. Leukotriene C4, eosinophil-derived neurotoxin (EDN) and eosinophil cationic
228 protein (ECP) are elevated in the respiratory tract in RSV-bronchiolitis, detectable in nasal
229 fluid (leukotriene C4 and ECP) and lower airway secretions (EDN and ECP) (31-33), while
230 one study did not find increased ECP levels (34). Nasopharyngeal ECP concentrations are
231 also elevated in children with RSV-LRTI (not specifically bronchiolitis) and URTI (35-39).
232 Nasal ECP concentrations correlate with nasal concentrations of the neutrophil
233 chemoattractant CCL-3 (MIP-1 α) and systemic neutrophil and eosinophil counts (37, 39).
234 Concentrations of CCL-5 (RANTES), an eosinophil chemoattractant, ECP and eotaxin all
235 increase during the progression from acute illness to recovery in RSV-LRTI and correlate
236 with respiratory tract eosinophil counts suggesting this response may have a role in resolution
237 (30, 38, 40, 41). In contrast to the apparent pro-resolution role of eosinophils themselves

during RSV infection it seems that a Th2-biased response, of which eosinophilia is a component, may be associated with more severe disease and this is discussed in detail in the section on Th2 responses below.

T-lymphocytes

An initial transient systemic T-cell lymphopenia occurs during RSV-LRTI. Counts of CD8+, CD4+, CD3+ and $\gamma\delta$ -T-cells are all reduced, compared to convalescence and non-infected infants (2, 15, 16, 18, 19, 30, 42-44). There is no increased expression of CD11a (LFA-1 α) in circulating T-cells suggesting that these cells are not activated, nor is there increased expression of CTLA-4, a marker of down-regulated T-cell activation (45, 46). Absolute T-cell counts during RSV-infection are inversely associated with age, thus T-cell lymphopenia is more pronounced in younger patients (42). Children with more severe illness and those requiring ventilation have reduced circulating T-cell counts (all sub-sets) compared to those with less severe infection and in lung tissue from fatal cases CD4+ and CD8+ T-cells are sparse (3, 16, 43, 47, 48). During the course of disease, circulating CD8+ T-cell counts increase (16, 49). In mechanically ventilated infants with severe RSV-LRTI, systemic effector CD8+ T-cell counts are low during maximum symptoms and viral load and then peak during convalescence (after the systemic neutrophil response) (10, 49). At the time of ICU discharge, circulating CD8+ T-cell counts are temporarily elevated, whereas neutrophils are normal.

Circulating FOXP3 mRNA and counts of FOXP3+ CD4+ regulatory T-cells (comprising suppressive resting Treg cells [CD45RA+ FOXP3^{lo}] and suppressive activated Treg cells [CD45RA+ FOXP3^{hi}]) are reduced in infants hospitalized with RSV-bronchiolitis and for at

least 3 weeks following acute infection (50, 51). Whether this represents apoptosis or recruitment to the lungs is unknown. Absolute counts of circulating regulatory T-cells do not correlate with disease severity (52).

CD4⁺ and CD8⁺ T-cells are present in BAL obtained from infants with RSV-LRTI, with a predominance of CD4⁺ T-cells (4, 5). During the course of infection, the expansion of CD8⁺ T-cells is greater than that of CD4⁺ T-cells, and the CD8⁺ T-cells exhibit an effector phenotype (HLA-DR⁺, granzyme-B⁺, CD38⁺). Lower respiratory tract (tracheal aspirate and BAL) granzyme A and B levels are elevated in ventilated patients and granzyme B is expressed by CD8⁺ T-cells (21). In bronchiolitis specifically, peripheral blood RSV-specific cell-mediated cytotoxic immune responses are more frequent in infants with mild compared to severe infection (53). In experimental RSV infection of adults, the arrival of CD8⁺ T-cells to the lungs (in BAL) is associated with a reduction in pulmonary viral load (54). The frequency of pre-existing RSV-specific pulmonary CD8⁺ T-cells in BAL is inversely associated with pulmonary viral load and symptom severity.

During acute infection, there is up-regulation of Fas and TRAIL receptor expression on circulating CD4⁺ and CD8⁺ T-cells compared to convalescence (42). Systemic concentrations of soluble Fas ligand and caspase-1 are elevated. An inverse correlation exists between CD4⁺ T-cell Fas expression and cell counts. Therefore, one mechanism underlying systemic lymphopenia may be the induction of T-cell apoptosis as a viral immune evasion strategy (Figure 1a). Furthermore, programmed cell death 1 (PD-1) protein expression is specifically up-regulated on pulmonary CD8⁺ T-cells during RSV-LRTI (55). PD-1 is a T-cell co-inhibitory receptor that is inhibitory to activated T-cells, therefore PD-1 upregulation could be another immune evasion strategy to blunt the cytotoxic T-cell response (Figure 1b).

RSV infection may also impair differentiation of CD8⁺ T-cells into memory cells by inducing mammalian target of rapamycin (mTOR) activation (Figure 1c) (56). mTOR mRNA expression is increased in the lungs of infants with RSV-bronchiolitis compared to human metapneumovirus and rhinovirus infection (and healthy controls) and the RSV cases have a higher proportion of CD8⁺mTORser2448⁺ T cells, indicating activation of the mTOR pathway by phosphorylation on serine 2448 (56). Higher prolactin and lower leptin levels have been associated with lymphopenia in severe RSV infection suggesting a neuroendocrine component although these hormonal differences could also be explained by the systemic effects of critical illness (57).

Defective T-cell responses

Deficits in systemic CD4⁺ and CD8⁺ T-cell responses may contribute to RSV susceptibility in the elderly as these subjects have lower levels of RSV-specific CD4⁺ and CD8⁺ T-cells compared to younger adults (58, 59). Interestingly, there is no decrease in the level of influenza virus-specific CD8⁺ T-cells with increasing age (59). Furthermore, immunosuppressant drugs prescribed for solid organ transplant recipients (glucocorticoids, calcineurin inhibitors, azathioprine, mycophenolate mofetil, sirolimus) all have inhibitory activity against T-cells thus impairing the ability of these patients to clear opportunistic RSV infection, resulting in more severe RSV disease (60). Similarly, haematopoietic stem cell transplant recipients are also at increased risk of severe RSV disease and peripheral blood lymphopenia has been identified as a specific risk factor for RSV-LRTI (61)

Cellular Response in Term and Pre-Term Infants

Total cellularity, neutrophil counts, macrophage counts and lymphocyte counts in BAL from infants ventilated due to RSV-bronchiolitis are all higher in term compared to pre-term infants, possibly related to immune system maturation (62).

B-LYMPHOCYTE RESPONSES AND ANTIBODY PRODUCTION DURING RSV INFECTION

Antibody Production and B-Lymphocyte Stimulation

There is an increase in circulating B-cells, including mature (CD19⁺ CD5⁺) and precursor (CD19⁺ CD10⁺) cells, in infants with RSV-LRTI and CD20⁺ B-cells and IgM⁺, IgG⁺, and IgA⁺ plasma cells are prominent in post-mortem lung tissue from infants with fatal RSV-bronchiolitis (43, 63, 64). Antibody responses target the F and G glycoproteins and increase between the acute and convalescent phases of natural primary infection of infants (65). Bronchiolitis may lead to a greater IgG response (66). Type I interferon (IFN) is implicated in early anti-viral B-cell responses and type I IFN-induced proteins (myxovirus resistance protein A, 2',5'-oligoadenylate synthetase 1) are present in high concentrations in bronchiolar and alveolar epithelial cells from RSV-infected infants (63). The B-cell stimulating factors, a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF), are also present, co-localized to infected epithelial cells. APRIL and BAFF receptors are expressed on a subset of perialveolar plasma cells. In infants ventilated due to severe RSV-bronchiolitis, pulmonary BAFF levels are increased (67, 68). BAFF mRNA levels are elevated in bronchial brushings, further suggesting airway epithelial cells are the source (67). RSV-IgA, -IgG, and -IgM are present in the lungs of infants with RSV-LRTI together with higher quantities of BAFF and APRIL, but lower levels of T-cell-dependent cytokines (IL-2, IL-4 and IL-10) (63, 69).

APRIL concentrations correlate positively with RSV-IgA and IgM levels and inversely with hypoxia. Thus, the pulmonary antibody response to RSV seems to be predominantly driven by T-cell-independent antibody production *via* B-cell stimulating factors (APRIL and BAFF), likely derived from infected pulmonary epithelial cells. In adults with RSV infection, a longer duration of virus shedding is associated with prolonged presence of circulating RSV-specific plasma cells, suggesting that persistent antigenic stimulation in the lung drives B-cell stimulation (70). Similarly, in elderly adults with nosocomial RSV infection, the highest IgG and IgA responses post-infection are seen in patients with more severe illness, perhaps correlating with viral load (71).

In comparison to healthy controls and rotavirus-infected infants, there is a high prevalence of anti HEp-2 (antinuclear) antibodies in infants with RSV-LRTI (72). Decay of these auto-antibodies was not studied (nor their presence pre-infection) but further investigation of subsequent development of autoimmune disease seems warranted.

Protective Effects of RSV-IgG and RSV-IgA

In experimental infection of healthy adults, higher pre-inoculation nasal RSV-IgA and serum anti-RSV neutralizing antibody titres are associated with protection from infection and reduced viral replication (73-77). RSV-specific nasal IgA, serum IgG and serum neutralizing titres in adults are also all associated with protection against natural RSV re-infection (78, 79). In experimental infections, nasal RSV-IgA appears to confer more protection than serum neutralizing antibody and the response may be more durable (74, 80). Similarly, in infants and children with natural infection it is the development of the IgA response that appears to correlate with recovery (81). During convalescence, circulating RSV-IgG but not -IgA

producing memory B-cells are present in contrast to natural influenza virus infection, where influenza-IgA producing memory B-cells are detectable (74). Overall, a possible deficit in IgA memory especially in children, when IgA appears to offer important protective immunity, may contribute to recurrent infections (74, 81). In contrast, in elderly patients it is a deficit in circulating serum neutralizing antibodies that appears to predispose to RSV disease (79).

In symptomatic RSV-infected and non-infected children, circulating RSV-IgG is present at the highest level in those <1 month old, likely derived from trans-placental maternal antibody transfer (82). IgG levels decrease after three months until two years, when levels increase again. The avidity of IgG is significantly lower amongst symptomatic RSV infected infants aged 1-3 months than in age-matched controls. Similarly, in children aged ≥ 24 months, total IgG affinity was lower for children with RSV-LRTI compared to milder URTI. Serum RSV-IgG and nasal RSV-IgA neutralizing activity is quantitatively higher in children aged 9-21 months compared to those aged 4-8 months (the age group with a higher incidence of RSV infection) (83). In infants there is a reverse correlation between pre-existing serum IgG and the development of nasal IgA following infection, suggesting maternally derived IgG may suppress the IgA response (84). These observations suggest that good IgG and IgA avidity for RSV contributes to protection against both the development of symptomatic infection and against more serious lung involvement. Following natural re-infection in adulthood, there is an eightfold increase in serum neutralization titre but this is short-lived, with a fourfold drop by one year in the majority of cases (85).

The serum neutralizing antibody response and nasal IgA and IgG response to the G glycoprotein are RSV-group specific (86, 87). In contrast, antibodies to the F glycoprotein are cross-reactive between RSV groups (88).

Other Mechanisms of RSV-specific Antibody Activity

Maximal cell-bound C3 is present during the convalescent phase and is associated with cell-bound IgG and IgM (89). RSV antigen containing immune complexes are detectable in the upper airways of infected infants from three days after the onset of illness, and detectable up to 36 days after (90). The appearance of such immune complexes coincides with the failure to detect RSV antigen in airway epithelial cells, possibly due to antibody-dependent cell-mediated cytotoxicity (ADCC), which occurs in infants with primary RSV infection (91). ADCC activity correlates with the titre of RSV-IgG in the upper airways and is greater during re-infection than primary infection.

Immunoglobulin E

An IgE response is mounted against the RSV F and G glycoproteins and may play a deleterious role (92). In infants with RSV-bronchiolitis there is a higher proportion of circulating CD23+ B-cells (CD23 is the low-affinity IgE receptor on mature and activated B-cells) than in non-RSV-bronchiolitis and non-infected infants (93). Nasopharyngeal RSV-IgE, histamine and leukotriene C4 levels are inter-related and associated with bronchiolitis (where peak levels correlate with hypoxia), compared to other manifestations of infection (URTI or pneumonia) (36, 94). In children with RSV-bronchiolitis or pneumonia, higher

serum IgE at admission has been associated with prolonged fever and worse symptoms and IgE titres and eosinophil counts with the development of wheeze during RSV-LRTI (95-97).

Th1 AND Th2 RESPONSES TO RSV INFECTION

Th1 Responses

Th1 responses are characterised by production of IFN- γ , IL-1, IL-2, IL-12, IL-18, TNF- α . IL-12 induces IFN- γ production and favours Th1 cell differentiation. The Th1 response is pro-inflammatory and important in the generation of cell-mediated immunity required for the control of intracellular pathogens. Therefore, it is an inherently appropriate response to viral infection.

Systemic

Markers of the Th1 response (IFN- γ , soluble tumor necrosis factor receptor II, soluble interleukin-2 receptor [sCD25]) are elevated in the circulation during RSV-LRTI and systemic IFN- γ exerts a protective effect (97-100). Children ≤ 6 months with RSV-bronchiolitis have a reduced IFN- γ response, possibly contributing to the increased incidence of RSV disease in the younger age group (101). In infants with RSV-LRTI, systemic IFN- γ concentrations are lower in those with severe disease (48, 98). Infants with RSV-bronchiolitis requiring ventilation have lower IFN- γ concentrations compared to those with milder disease and undetectable circulating IFN- γ positively correlates with the need for ventilation (102). Low IFN- γ :IL-10 ratios are associated with hypoxia and wheeze (99). During the acute phase of RSV-LRTI, peripheral blood mononuclear cell IFN- γ mRNA expression is lower in

hypoxic patients(47). Furthermore, circulating IL-12 levels are lower in severe RSV-LRTI compared to mild infections or controls (48, 98).

Respiratory tract

IFN- γ levels are also elevated in the nasal mucosa (37, 103-106) and in the lung (20, 106). The respiratory tract IFN- γ response exerts a protective effect, with lower IFN- γ production associated with increased severity scores, hypoxia and need for ventilation (106-110). In RSV-LRTI, the nasopharyngeal IFN- γ :IL-10 ratio increases from presentation to discharge, in parallel with clinical recovery, strengthening the association of IFN- γ with protection (41).

Other Th1-associated cytokines are also elevated in the nasal mucosa (IL-1, IL-2, IL-12, IL-18, TNF- α) (37, 111, 112) and in the lungs (IL-1, IL-2, TNF- α) (20, 113). TNF- α levels are highest during the acute phase of infection then decline during recovery (37, 105, 113-115). Raised IL-6 mRNA and protein have been observed in BAL and nasopharyngeal fluid from infants with severe RSV infection and a high ratio of IL-6:TNF- α is associated with reduced disease severity (113, 116). In children with only URTI there is reduced nasal production of anti-inflammatory IL-10 and this is inversely related to TNF- α production (117). It has been suggested that a reduction in IL-10 production facilitates a robust TNF- α response, limiting the infection to the upper airway.

Increased nasal concentrations of IL-1 α are associated with the need for ventilation in children with RSV-LRTI (118, 119). There is also an increase in nasal IL-18 concentrations and the number of IL-18 positive cells in children with RSV-bronchiolitis compared to URTI

(117). In bronchiolitis, nasal IL-18 production is associated with non-hypoxic infection, consistent with its role in stimulating IFN- γ production (117, 120).

Th2 Responses

The Th2 response, characterised by IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 production, is involved in the generation of antibody (in particular IgE) and eosinophil responses. This response is associated with atopy and also protection against parasitic infections, and may counteract and limit Th1-mediated inflammation.

Systemic

Systemic IL-4, IL-6, IL-10 and IL-13 levels are elevated in children with RSV-LRTI (37, 97, 101, 121-123). Systemic IL-6 and IL-10 levels correlate with disease severity in RSV-LRTI including the requirement of supplemental oxygen (99, 122, 124, 125). In comparison to influenza A virus infection, the systemic concentrations of IL-4, IL-5 and CCL-5 are higher during RSV-LRTI (126).

Respiratory tract

Elevated concentrations of IL-4, IL-6, IL-9, IL-10 and IL-13 have been found in nasal washes (37, 109, 127-130) and in the lung (20, 131-133) in children with RSV-LRTI. Respiratory tract IL-10 production appears to exert a protective effect in RSV-LRTI, with concentrations inversely correlating with the duration of required supplemental oxygen and symptom severity (108, 128, 132). In very young infants (<3 months) this effect appears to be reversed,

with IL-10 concentrations correlating with severity (125), and nasal IL-10:CCL-5 ratios are only inversely correlated with duration of mechanical ventilation when infants older than 5 months are considered (134).

IL-6 levels are strongly elevated in BAL from infants ventilated due to severe RSV-bronchiolitis (20, 113) and are elevated to a lesser extent in the respiratory tract in infants with milder infection (37, 117, 132). There are inconsistent data associating the nasal IL-6 response with severity. In infants with RSV-bronchiolitis, nasal IL-6 concentrations are higher in those requiring ventilation and correlate with the degree of hypoxia (111, 118, 135, 136). Similarly, adults hospitalised due to RSV infection have higher nasal IL-6 concentrations than those not requiring hospitalisation (137). In experimentally infected adults, nasal IL-6 concentration is positively correlated with viral load and symptom severity (138). In contrast, in a cohort of children with RSV-bronchiolitis, higher nasal IL-6 concentrations are associated with a shorter requirement for supplemental oxygen (108).

Th1/Th2 Balance

A high nasal and systemic IL-4:IFN- γ ratio, a marker of Th2-bias, is associated with severe (hypoxic) RSV-bronchiolitis (103, 123, 139). Independent of the ratio, IFN- γ concentrations are lower and IL-4 concentrations higher in infants with severe bronchiolitis. Also in severe RSV-bronchiolitis, circulating CXCR3⁺ T-cell (Th1) counts are significantly reduced during acute infection compared to convalescence, but CCR4⁺ T-cells (Th2) are not (140). An excessive Th2 or deficient Th1 response may be associated with the development of bronchiolitis compared to milder URTI with RSV: the nasal IL-4:IFN- γ and IL-10:IL-12 ratio is higher in infants with bronchiolitis (141). In a cohort of children with hypoxic RSV-LRTI,

comparison of systemic and respiratory tract cytokines showed a predominance of Th2 cytokines in nasopharyngeal fluid (higher pulmonary:systemic ratios of IL-4:IL-12, IL-10:IL-2, IL-10:IFN- γ , IL-6:IFN- γ , IL-6:IL-2) (37). Overall, these data suggest a Th2-biased response may be associated with more severe manifestations of RSV infection, consistent with it being either an inappropriate response to acute viral infection or one that is required to limit a potentially detrimental Th-1 response in severe RSV infection.

However, such findings are not entirely consistent throughout the literature and there are reports of elevated IFN- γ :IL-4 ratios in children with more severe manifestations of RSV infection (bronchiolitis, pneumonia, any LRTI) compared to controls albeit not stratified by severity of infection within the groups (98, 142, 143). A heterogeneous polarization of pulmonary Th responses in infants with severe RSV-bronchiolitis has also been described, with 25% of infants only expressing IFN- γ and 50% only expressing IL-4; although again overall supporting a Th2-bias in severe disease (144). In comparison to infection with human metapneumovirus (hMPV), infants with RSV infection have similar nasopharyngeal IFN- γ levels but higher IL-4 consistent with a Th2-biased response that is distinct from the response to hMPV (34).

There are lower counts of *in vivo* RSV-specific T-cells in the elderly and in *in vitro* experiments both isolated T-cells and peripheral blood mononuclear cells from healthy elderly patients produce less IFN- γ when stimulated with RSV F protein or RSV respectively (58, 59, 145). Although this finding has not been confirmed by *in vivo* experiments, it does hint at a defective Th1 response in the elderly which may contribute to the higher incidence of severe RSV disease in this population.

CHEMOKINES, CYTOKINES AND OTHER IMMUNE MOLECULES EXPRESSED DURING RSV INFECTION

Overview

A comprehensive list of immune and lung structural proteins involved in the response to RSV infection is presented in Table 1. Key molecules are discussed here.

Interleukin-8

Systemic and respiratory tract production of IL-8, a neutrophil chemoattractant, is increased during RSV-LRTI and circulating concentrations normalise during convalescence (37, 102, 105, 111, 121, 122, 133, 146-149). Higher circulating and respiratory tract IL-8 levels are associated with hypoxia and need for ventilation in infants (18, 37, 102, 135, 136, 147). IL-8 production in the nasal mucosa is also higher during LRTI in children caused by RSV compared to rhinovirus (150). When comparing term and pre-term infants with RSV-LRTI of similar severity, nasal IL-8 and leucocyte counts are higher in the term infants suggesting a more vigorous inflammatory response (151).

Interleukin-17A

Compared to non-RSV-LRTI, circulating Th17 cell counts and IL-17 levels are higher in infants with RSV-bronchiolitis (51). In these infants, nasal concentrations of pro-inflammatory IL-17A are higher in patients requiring ventilation (118). When ventilated, tracheal IL-17A concentrations positively correlate with neutrophil counts (152). In infants

with mild bronchiolitis, although nasal IL-17A levels are lower initially, they increase during the convalescent phase, hinting at a dual role for IL-17A: deleterious in the acute phase, possibly related to neutrophil recruitment, but potentially involved in the resolution of milder infections (118).

CC Chemokines

CCL-5 (RANTES), eotaxin and CCL-3 (MIP-1 α) production in the nasal mucosa and lung (in BAL) is increased during RSV-LRTI and bronchiolitis (32, 37, 38, 129, 132, 133, 143, 149, 153-155). However, nasal and systemic CCL-5 concentrations are lower in patients requiring ventilation (18, 132) inversely correlating with the duration of ventilation and required supplemental oxygen. In RSV-LRTI, the duration of required supplemental oxygen is positively associated with nasal CCL-3 and inversely with CCL-4 (MIP-1 β) (107, 108). CCL-3 and eotaxin concentrations in the nasal mucosa are higher in hypoxic bronchiolitis compared to URTI or non-hypoxic bronchiolitis (103, 155, 156). Nasal CCL-3 concentrations are higher in RSV-infected adults who require hospitalisation, compared to those who do not, and are associated with symptom severity in experimentally infected adults (137, 138). However, one study of RSV-LRTI found that increased nasal CCL-2 (MCP-1), CCL-3 and CCL-4 are all positively associated with severity (119).

Pattern Recognition Receptors (PRR)

PRRs are involved in innate immune recognition of viral pathogens in order to stimulate interferon and cytokine responses. In comparison to healthy controls or infants with rhinovirus or bocavirus infection, in infants with RSV-bronchiolitis there is increased

pulmonary expression of TLR-7, TLR-8, RIG-1 and MDA-5 (157). RIG-1 mRNA in the lungs correlated with RSV viral load (157). Furthermore, an individual's TLR4 genotype influences the severity of RSV-bronchiolitis and this is significantly influenced by environmental lipopolysaccharide exposure (139).

Innate Interferons

IFN- α is produced systemically and in the respiratory tract in response to RSV infection (158). Nasopharyngeal IFN- α titres peak on day 1 of illness and remain elevated for ~6 days, then decrease in parallel with nasopharyngeal RSV antigen levels (158). In peripheral blood, IFN- α levels peak by day 2. Infants aged less than 3 months produce the lowest levels of IFN- α in both the nasopharynx and peripheral blood (158). RSV may be a comparatively weak inducer of type I IFN since nasopharyngeal IFN- α levels are higher in infants with influenza virus, adenovirus and parainfluenza virus infection (158).

Type III interferons (IFN- λ) are produced in response to viral infection and have type I IFN-like activities. Their receptor complex is primarily expressed on epithelial cells and IFN- λ responsiveness is greatest in organs with high epithelial content such as the lungs. There is a IFN- λ response to RSV-bronchiolitis, with higher nasal levels of IFN- λ 1-3 seen compared to rhinovirus infection (159, 160). IFN- λ mRNA levels correlate with IFN-stimulated gene expression (*MxA* and *ISG56*) (159). Despite their association with antiviral gene expression, higher nasal IFN- λ -1 levels are associated with increased disease severity (159).

Immunostimulatory defective viral genomes (iDVGs) have been detected in the nasal fluid of around half of RSV-infected children in one study (161). These RSV genomes have large

deletions rendering them unable to replicate without the presence of helper virus. The presence of iDVGs correlates with mRNA levels of *IFNA4* and the ISGs *IFIT1* and *RSAD2*, suggesting they are sufficient to stimulate an innate interferon response (161).

microRNA

Viral infection (especially with RNA viruses) can subvert cellular microRNA expression potentially to the benefit of the virus. A distinct microRNA expression profile is detectable in the nasal mucosa of RSV-infected infants compared to non-infected controls (downregulation of miR-34b, miR-34c, miR-125b, miR-29c, miR-125a, miR-429 and miR-27b; upregulation of miR-155, miR-31, miR-203a, miR-16 and let-7d) (162). miR-125a and miR-429 are downregulated in mild but not severe infection; the former has roles in NF-kappa B signaling and macrophage function (162). miR-26b (thought to target TLR4 based on miRNA target prediction software) has been studied in PBMCs from children with RSV-bronchiolitis where it is up-regulated, negatively correlating with TLR4 expression (163).

GLOBAL HOST TRANSCRIPTIONAL RESPONSE TO RSV INFECTION

Genes and pathways associated with neutrophil function, interferon signalling (including *STAT1*, *STAT2*, *IFITM1*, *OAS2*, *MX1*, *IFI27*, *IFI35* and *IFIT3*), interferon-inducible proteins (including *IFI44*, *EIF2AK2*, *IFI44L*, *IFI6*, *OAS3* and *GIP2*), dendritic cell maturation and inflammation are up-regulated in the circulation of children with RSV infection (164-166). Genes and pathways associated with NK cell, B-cell and T-cell responses, cytotoxic lymphocyte-mediated apoptosis of target cells, HLA class I and II and antigen presentation are under-expressed (164-166). Under-expression is greater in infants <6 months compared to

those aged 6-24 months (164) and may reflect either low gene expression or migration of peripheral blood immune cells to the infected tissues. In severe disease there is greater up-regulation of neutrophil and inflammatory gene expression and greater suppression of T-cell, NK cell and plasma cell associated-genes (164). In comparison, this dysregulation of genes relating to neutrophil, B-cell and T-cell function is not seen in children with rhinovirus or influenza virus infection (164).

A different transcriptional response is seen in the upper airways of RSV-infected children. In infants requiring supplemental oxygen or mechanical ventilation, *ubiquitin D*, *tetraspanin 8*, *mucin 13* and *β -microseminoprotein* are up-regulated and *chemokine ligand 7* is down-regulated compared to milder RSV infection (167).

RELATIONSHIP BETWEEN MOLECULAR AND CELLULAR IMMUNE RESPONSES TO RSV AND PATHOPHYSIOLOGY

Molecular and cellular events during RSV infection are reflected in changes in host physiology observed during the course of disease (Figure 1). The initial development of cough, wheezing and tachypnoea, usually peaking on days 4-5, develops in parallel to the maximal neutrophil response and viral load (10). This is followed by a convalescent period with a CD8⁺ T-cell predominant response involved in viral clearance which coincides with the reduction in the above respiratory symptoms over a period of 2-3 weeks.

Many of the different cytokines, chemokines and other immune molecules that are involved in the immune response to RSV infection have been associated with protective or deleterious effects, as listed in Table 1, depending on the perceived severity of disease in the studied

patients. This is usually based on the need for ICU admission, endotracheal intubation and mechanical ventilation, but also on composite scores of clinical parameters including respiratory rate, oxygen saturations, the need for supplemental oxygen or the need for hospitalisation.

We know that pre-existing differences in immune status may modulate molecular and cellular responses during RSV infection. Younger infants have more pronounced lymphopenia and reduced IFN- γ responses possibly reflecting the immunological immaturity of early life (42, 101). Term infants seem to have a stronger inflammatory response with higher leucocyte counts and IL-8 levels compared to preterm infants (151). On the other hand, preterm babies may have an inadequate antiviral response with reduced pulmonary pDC counts (20). These observations may provide an explanation for the increased frequency of severe RSV disease in preterm and younger term born infants.

Furthermore, early life microbiome changes in the gut and respiratory tract may influence the host immune responses during RSV disease (168), similar to the distinct patterns of nasopharyngeal microbiota development that have been reported in young infants with cystic fibrosis (169). Certainly, associations between the respiratory and gut microbiome, host transcriptional immune responses, RSV load and clinical status are now evident and require further detailed investigation (170).

RSV INFECTION AND SUBSEQUENT RESPIRATORY HEALTH

RSV-bronchiolitis during early life has been associated with an increase in susceptibility to subsequent episodic wheeze, physician diagnosed asthma and decreased FEV₁ and FVC measurements on pulmonary function testing (171). Evidence for a causal relationship comes from an intervention trial in premature infants (gestational age 33-35 weeks) who received either palivizumab, a humanized monoclonal anti-RSV IgG used in the prevention of severe RSV disease, or placebo during RSV season (172). Palivizumab treatment almost halved (-46.4%) the proportion of infants with subsequent recurrent wheeze compared to placebo. Possible molecular and cellular explanations for such a relationship have been described. There is little human data on potential immune mechanisms for the long term effects of RSV-bronchiolitis, but levels of the cytokines IL-3 and IL-12p40 during RSV disease have been found to correlate with subsequent development of recurrent wheeze (133). Furthermore, elevation of VEGF, G-CSF, and IL-10 persists after the RSV episode, all mediators that have been related to asthma and post-virus induced wheeze (173). Higher proportions of nasal pDCs may reflect a heightened antiviral response in the respiratory tract, potentially due to higher viral load, leading to the development of recurrent wheeze and asthma (174). IL-33, although not reported to be associated with severity of disease, has also been implicated in a Th2-biased response to RSV and may relate to RSV-mediated asthma in later life (130).

KEY DIFFERENCES IN THE IMMUNE RESPONSE TO RSV BETWEEN ANIMAL MODELS AND HUMANS

Contemporary data from animal models of RSV infection have been comprehensively reviewed by Borchers and colleagues recently (175). Although similarities are evident the critical fact remains that human RSV has no animal reservoir and has evolved to infect humans as its natural host, not the commonly used rodent models, which require infection

doses far in excess of those needed for human RSV infection. Neutrophilic inflammation contributes significantly to pathogenesis in humans (where neutrophils can constitute up to 85% of BAL cell counts) but appears to have a less dominant role in mice (15-20% of cells) (67). In humans the contribution of Th1 and Th2 immune responses is variable and related to pathogenesis, whereas in mice there is generally a robust and reliable Th1 (IFN- γ) response (175). The evidence for an important contribution of eosinophils in humans has been reviewed earlier, but there is no evidence that these cells have a major role in the pathogenesis of disease in mice (175, 176).

CONCLUSION

By synthesizing the results of a systematic literature review of data exclusively from infected humans, we propose the following model to describe our current understanding of the immune response to RSV infection in humans (Figure 2).

Large quantities of pro-inflammatory cytokines are produced in the respiratory tract, with an initial strong activated pulmonary and systemic neutrophil response which correlates with disease severity and is mediated by the neutrophil chemoattractant IL-8. Eosinophil degranulation occurs in the lungs during RSV-bronchiolitis and there may also be a role for CCL-5-mediated eosinophil recruitment to the lungs during recovery from RSV-LRTI. Dendritic cells migrate into the lungs where they are the primary antigen presenting cell. Circulating cDCs exhibit an activated phenotype, and pulmonary cDC counts correlate with pro-inflammatory and T-cell derived cytokine concentrations suggesting they contribute to the inflammatory response in a potentially deleterious manner. Alveolar macrophages have an immune-regulatory and antigen presenting role.

732

733 Initially, there is a systemic CD4⁺ and CD8⁺ T-cell lymphopenia, without evidence for
734 pulmonary sequestration of T-cells. There is active T-cell apoptosis, upregulation of the T-
735 cell co-inhibitory molecule PD-1 and mTOR-mediated suppression of memory CD8⁺ T-cell
736 differentiation, suggesting T-cell interference is a key viral immune evasion strategy (Figure
737 1). Following the initial neutrophilic response there is a pulmonary CD8⁺ T-cell response
738 coinciding with clearance of RSV from the lungs. CD8⁺ T-cells are protective, likely
739 mediating viral clearance and therefore enabling resolution of infection. Humoral immunity
740 to RSV re-infection is incomplete but RSV-specific circulating IgG and secretory IgA are
741 protective against infection and possibly modify the severity of infection. T-cell-independent
742 B-cell antibody production via B-cell stimulating factors (BAFF and APRIL) derived from
743 airway epithelium seems to play a major role in protective antibody generation. On the other
744 hand, RSV-IgE production is associated with bronchiolitis, where it may have a deleterious
745 effect. There is strong evidence that IFN- γ (and related to this, IL-12 and IL-18 which
746 promote IFN- γ production/Th1 differentiation) has a protective role in RSV infection. In
747 contrast, a Th2-biased response may be associated with more severe disease manifestations.
748 Global host transcriptional profiling reveals up-regulation of innate inflammatory (e.g.
749 neutrophil related) genes and suppression of genes associated with the adaptive immune
750 response. This is exaggerated in severe disease and is specific to RSV infection. Other
751 cytokines (particularly IL-17A), chemokines (particularly CCL-5 and CCL-3) and local
752 innate immune factors (cathelicidins, IFN- λ , G-CSF, sICAM-1) have also been associated
753 with the course of disease. Elderly patients are at increased risk of severe RSV disease and
754 this susceptibility may relate to defects in circulating neutralizing antibody titres and RSV-
755 specific CD4⁺ and CD8⁺ T-cells.

756

Overall, neutrophilic pulmonary inflammation is incriminated as a damaging process and protective effects of CD8⁺ T-cells and IFN- γ production are consistently reported. While these processes may be important therapeutic targets to modulate the immunopathogenesis of RSV infection, less well characterised immune processes, especially occurring in the lower airways and lung, require further investigation.

ACKNOWLEDGEMENTS

We would like to thank Ronnie Grant and Patrick Lane for their assistance with the illustrations used in Figures 1 and 2.

REFERENCES

1. **Smith PK, Wang SZ, Dowling KD, Forsyth KD.** 2001. Leucocyte populations in respiratory syncytial virus-induced bronchiolitis. *Journal of Paediatrics and Child Health* **37**:146-151.
2. **O'Donnell DR, Carrington D.** 2002. Peripheral blood lymphopenia and neutrophilia in children with severe respiratory syncytial virus disease. *Pediatric Pulmonology* **34**:128-130.
3. **Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez K, Velozo L, Jafri H, Chavez-Bueno S, Ogra PL, McKinney L, Reed JL, Welliver RC.** 2007. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. *Journal of Infectious Diseases* **195**:1126-1136.
4. **Heidema J, Lukens MV, van Maren WWC, van Dijk MEA, Otten HG, van Vught AJ, van der Werff DBM, van Gestel SJP, Semple MG, Smyth RL, Kimpen JLL, van Bleek GM.** 2007. CD8(+) T cell responses in bronchoalveolar lavage fluid and peripheral blood

- mononuclear cells of infants with severe primary respiratory syncytial virus infections. *Journal of Immunology* **179**:8410-8417.
5. **Everard ML, Swarbrick A, Wraitham M, McIntyre J, Dunkley C, James PD, Sewell HF, Milner AD.** 1994. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. *Archives of Disease in Childhood* **71**:428-432.
 6. **Emboriadou M, Hatzistilianou M, Magnisali C, Sakelaropoulou A, Exintari M, Conti P, Aivazis V.** 2007. Human neutrophil elastase in RSV bronchiolitis. *Annals of Clinical and Laboratory Science* **37**:79-84.
 7. **Abu-Harb M, Bell F, Finn A, Rao WH, Nixon L, Shale D, Everard ML.** 1999. IL-8 and neutrophil elastase levels in the respiratory tract of infants with RSV bronchiolitis. *European Respiratory Journal* **14**:139-143.
 8. **Wang SZ, Smith PK, Lovejoy M, Bowden JJ, Alpers JH, Forsyth KD.** 1998. The apoptosis of neutrophils is accelerated in respiratory syncytial virus (RSV)-induced bronchiolitis. *Clinical & Experimental Immunology* **114**:49-54.
 9. **Wang SZ, Smith PK, Lovejoy M, Bowden JJ, Alpers JH, Forsyth KD.** 1998. Shedding of L-selectin and PECAM-1 and upregulation of Mac-1 and ICAM-1 on neutrophils in RSV bronchiolitis. *American Journal of Physiology-Lung Cellular and Molecular Physiology* **275**:L983-L989.
 10. **Lukens MV, van de Pol AC, Coenjaerts FEJ, Jansen NJG, Kamp VM, Kimpen JLL, Rossen JWA, Ulfman LH, Tacke CEA, Viveen MC, Koenderman L, Wolfs TFW, van Bleek GM.** 2010. A Systemic Neutrophil Response Precedes Robust CD8(+) T-Cell Activation during Natural Respiratory Syncytial Virus Infection in Infants. *Journal of Virology* **84**:2374-2383.
 11. **Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS.** 2007. The histopathology of fatal untreated human respiratory syncytial virus infection. *Modern Pathology* **20**:108-119.
 12. **Halfhide CP, Flanagan BF, Brearey SP, Hunt JA, Fonceca AM, McNamara PS, Howarth D, Edwards S, Smyth RL.** 2011. Respiratory Syncytial Virus Binds and

- 808 Undergoes Transcription in Neutrophils From the Blood and Airways of Infants With Severe
809 Bronchiolitis. *Journal of Infectious Diseases* **204**:451-458.
- 810 13. **Yui I, Hoshi A, Shigeta Y, Takami T, Nakayama T.** 2003. Detection of human respiratory
811 syncytial virus sequences in peripheral blood mononuclear cells. *Journal of Medical Virology*
812 **70**:481-489.
- 813 14. **Cortjens B, de Boer OJ, de Jong R, Antonis AFG, Pineros YSS, Lutter R, van Woensel
814 JBM, Bem RA.** 2016. Neutrophil extracellular traps cause airway obstruction during
815 respiratory syncytial virus disease. *Journal of Pathology* **238**:401-411.
- 816 15. **Larranaga CL, Ampuero SL, Luchsinger VF, Carrion FA, Aguilar NV, Morales PR,
817 Palomino MAM, Tapia LF, Avendano LF.** 2009. Impaired Immune Response in Severe
818 Human Lower Tract Respiratory Infection by Respiratory Syncytial Virus. *Pediatric
819 Infectious Disease Journal* **28**:867-873.
- 820 16. **De Weerd W, Twilhaar WN, Kimpen JL.** 1998. T cell subset analysis in peripheral blood
821 of children with RSV bronchiolitis. *Scandinavian Journal of Infectious Diseases* **30**:77-80.
- 822 17. **Noyola DE, Juarez-Vega G, Monjaras-Avila C, Escalante-Padron F, Rangel-Ramirez V,
823 Cadena-Mota S, Monsivais-Urenda A, Garcia-Sepulveda CA, Gonzalez-Amaro R.** 2015.
824 NK cell immunophenotypic and genotypic analysis of infants with severe respiratory
825 syncytial virus infection. *Microbiology and Immunology* **59**:389-397.
- 826 18. **Brand HK, Ferwerda G, Preijers F, de Groot R, Neeleman C, Staal FJT, Warris A,
827 Hermans PWM.** 2013. CD4(+)T-cell counts and interleukin-8 and CCL-5 plasma
828 concentrations discriminate disease severity in children with RSV infection. *Pediatric
829 Research* **73**:187-193.
- 830 19. **Brand HK, Ahout IML, de Ridder D, van Diepen A, Li Y, Zaalberg M, Andeweg A,
831 Roeleveld N, de Groot R, Warris A, Hermans PWM, Ferwerda G, Staal FJT.** 2015.
832 Olfactomedin 4 Serves as a Marker for Disease Severity in Pediatric Respiratory Syncytial
833 Virus (RSV) Infection. *PLoS One* **10**:e0131927.
- 834 20. **Kerrin A, Fitch P, Errington C, Kerr D, Waxman L, Riding K, McCormack J,
835 Mehendele F, McSorley H, MacKenzie K, Wronski S, Braun A, Levin R, Theilen U,**

- 836 **Schwarze J.** 2016. Differential lower airway dendritic cell patterns may reveal distinct
837 endotypes of RSV bronchiolitis. *Thorax* [Epub ahead of print].
- 838 21. **Bem RA, Bos AP, Bots M, Wolbink AM, Van Ham SM, Medema JP, Lutter R, Van**
839 **Woensel JBM.** 2008. Activation of the granzyme pathway in children with severe respiratory
840 syncytial virus infection. *Pediatric Research* **63**:650-655.
- 841 22. **Gill MA, Long K, Kwon T, Muniz L, Mejias A, Connolly J, Roy L, Banchereau J,**
842 **Ramilo O.** 2008. Differential recruitment of dendritic cells and monocytes to respiratory
843 mucosal sites in children with influenza virus or respiratory syncytial virus infection. *J Infect*
844 *Dis* **198**:1667-1676.
- 845 23. **Gill MA, Palucka AK, Barton T, Ghaffar F, Jafri H, Banchereau J, Ramilo O.** 2005.
846 Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with
847 respiratory syncytial virus and other viral respiratory infections. *Journal of Infectious*
848 *Diseases* **191**:1105-1115.
- 849 24. **Weng KZ, Zhang JX, Mei XQ, Wu A, Zhang BZ, Cai MY, Zheng YH, Ke ZY.** 2014.
850 Lower number of plasmacytoid dendritic cells in peripheral blood of children with
851 bronchiolitis following respiratory syncytial virus infection. *Influenza and Other Respiratory*
852 *Viruses* **8**:469-473.
- 853 25. **Midulla F, Villani A, Panuska JR, Dab I, Kolls JK, Merolla R, Ronchetti R.** 1993.
854 Respiratory syncytial virus lung infection in infants: immunoregulatory role of infected
855 alveolar macrophages. *Journal of Infectious Diseases* **168**:1515-1519.
- 856 26. **Panuska JR, Hertz MI, Taraf H, Villani A, Cirino NM.** 1992. Respiratory syncytial virus
857 infection of alveolar macrophages in adult transplant patients. *American Review of*
858 *Respiratory Disease* **145**:934-939.
- 859 27. **Bendelja K, Vojvoda V, Aberle N, Cepin-Bogovic J, Gagro A, Mlinaric-Galinovic G,**
860 **Rabatic S.** 2010. Decreased Toll-like receptor 8 expression and lower TNF-alpha synthesis in
861 infants with acute RSV infection. *Respir Res* **11**:143.
- 862 28. **Gagro A, Tominac M, Krsulovic-Hresic V, Bace A, Matic M, Drazenovic V, Mlinaric-**
863 **Galinovic G, Kosor E, Gotovac K, Bolanca I, Batinica S, Rabatic S.** 2004. Increased Toll-

- like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis. *Clinical and Experimental Immunology* **135**:267-272.
29. **Lindemans CA, Kimpen JLL, Luijk B, Heidema J, Kanters D, van der Ent CK, Koenderman L.** 2006. Systemic eosinophil response induced by respiratory syncytial virus. *Clinical and Experimental Immunology* **144**:409-417.
30. **Kawasaki Y, Hosoya M, Kanno H, Suzuki H.** 2006. Serum regulated upon activation, normal T cell expressed and presumably secreted concentrations and eosinophils in respiratory syncytial virus infection. *Pediatrics International* **48**:257-260.
31. **Dimova-Yaneva D, Russell D, Main M, Brooker RJ, Helms PJ.** 2004. Eosinophil activation and cysteinyl leukotriene production in infants with respiratory syncytial virus bronchiolitis. *Clinical and Experimental Allergy* **34**:555-558.
32. **Kim HH, Lee MH, Lee JS.** 2007. Eosinophil cationic protein and chemokines in nasopharyngeal secretions of infants with respiratory syncytial virus (RSV) bronchiolitis and non-RSV bronchiolitis. *Journal of Korean Medical Science* **22**:37-42.
33. **Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB.** 1999. Respiratory syncytial virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. *Am J Respir Crit Care Med* **159**:1918-1924.
34. **Park JS, Kim YH, Kwon E, Callaway Z, Fujisawa T, Kim CK.** 2015. Different inflammatory mechanisms of human metapneumovirus and respiratory syncytial virus. *Journal of Allergy and Clinical Immunology* **135**:AB150.
35. **Garofalo R, Kimpen JL, Welliver RC, Ogra PL.** 1992. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. *J Pediatr* **120**:28-32.
36. **Volovitz B, Welliver RC, De Castro G, Krystofik DA, Ogra PL.** 1988. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. *Pediatr Res* **24**:504-507.
37. **Bermejo-Martin JF, Garcia-Arevalo MC, De Lejarazu RO, Ardura J, Eiros JM, Alonso A, Matias V, Pino M, Bernardo D, Arranz E, Blanco-Quiros A.** 2007. Predominance of

- 892 Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during
893 severe respiratory syncytial virus infection in children. *European Cytokine Network* **18**:162-
894 167.
- 895 38. **Chung HL, Kim SG.** 2002. RANTES may be predictive of later recurrent wheezing after
896 respiratory syncytial virus bronchiolitis in infants. *Annals of Allergy Asthma & Immunology*
897 **88**:463-467.
- 898 39. **Okamoto N, Ikeda M, Okuda M, Sakamoto T, Takasugi M, Takahashi N, Araki T,**
899 **Morishima T, Yasui K.** 2011. Increased eosinophilic cationic protein in nasal fluid in
900 hospitalized wheezy infants with RSV infection. *Allergology International* **60**:467-472.
- 901 40. **Smyth RL, Fletcher JN, Thomas HM, Hart CA.** 1997. Immunological responses to
902 respiratory syncytial virus infection in infancy. *Archives of Disease in Childhood* **76**:210-
903 214.
- 904 41. **Bermejo-Martin JF, Garcia-Arevalo MC, Alonso A, De Lejarazu RO, Pino M, Resino S,**
905 **Tenorio A, Bernardo D, Leon AJ, Garrote JA, Ardura J, Dominguez-Gil M, Eiros JM,**
906 **Blanco-Quiros A, Munoz-Fernandez MA, Kelvin DJ, Arranz E.** 2007. Persistence of
907 proinflammatory response after severe respiratory syncytial virus disease in children. *J*
908 *Allergy Clin Immunol* **119**:1547-1550.
- 909 42. **Roe MFE, Bloxham DM, White DK, Ross-Russell RI, Tasker RTC, O'Donnell DR.** 2004.
910 Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis. *Clinical and*
911 *Experimental Immunology* **137**:139-145.
- 912 43. **Roman M, Calhoun WJ, Hinton KL, Avendano LF, Simon V, Escobar AM, Gaggero A,**
913 **Diaz PV.** 1997. Respiratory syncytial virus infection in infants is associated with predominant
914 Th-2-like response. *American Journal of Respiratory & Critical Care Medicine* **156**:190-195.
- 915 44. **Ribeiro LZG, Tripp RA, Rossi LMG, Palma PVB, Yokosawa J, Mantese OC, Oliveira**
916 **TFM, Nepomuceno LL, Queiroz DAO.** 2008. Serum mannose-binding lectin levels are
917 linked with respiratory syncytial virus (RSV) disease. *Journal of Clinical Immunology*
918 **28**:166-173.

- 919 45. **Ayukawa H, Matsubara T, Kaneko M, Hasegawa M, Ichiyama T, Furukawa S.** 2004.
920 Expression of CTLA-4 (CD152) in peripheral blood T cells of children with influenza virus
921 infection including encephalopathy in comparison with respiratory syncytial virus infection.
922 *Clinical and Experimental Immunology* **137**:151-155.
- 923 46. **Koga M, Matsuoka T, Matsubara T, Katayama K, Furukawa S.** 2000. Different
924 expression of ICAM-1 and LFA-1 alpha by peripheral leukocytes during respiratory syncytial
925 virus and influenza virus infection in young children. *Scand J Infect Dis* **32**:7-11.
- 926 47. **Aberle JH, Aberle SW, Dworzak MN, Mandl CW, Rebhandl W, Vollnhofer G, Kundi**
927 **M, Popow-Kraupp T.** 1999. Reduced interferon-gamma expression in peripheral blood
928 mononuclear cells of infants with severe respiratory syncytial virus disease. *American Journal*
929 *of Respiratory and Critical Care Medicine* **160**:1263-1268.
- 930 48. **Pinto RA, Arredondo SM, Bono MR, Gaggero AA, Diaz PV.** 2006. T helper 1/T helper 2
931 cytokine imbalance in respiratory syncytial virus infection is associated with increased
932 endogenous plasma cortisol. *Pediatrics* **117**:e878-886.
- 933 49. **de Waal L, Koopman LP, van Benten IJ, Brandenburg AH, Mulder PGH, de Swart RL,**
934 **Fokkens WJ, Neijens HJ, Osterhaus A.** 2003. Moderate local and systemic respiratory
935 syncytial virus-specific T-cell responses upon mild or subclinical RSV infection. *Journal of*
936 *Medical Virology* **70**:309-318.
- 937 50. **Raiden S, Pandolfi J, Payaslian F, Anderson M, Rivarola N, Ferrero F, Urtasun M,**
938 **Fainboim L, Geffner J, Arruvito L.** 2014. Depletion of circulating regulatory T cells during
939 severe respiratory syncytial virus infection in young children. *American Journal of*
940 *Respiratory & Critical Care Medicine* **189**:865-868.
- 941 51. **Li B, Wu FL, Feng XB, Sun DK, Cui QQ, Zhao ZX.** 2012. [Changes and the clinical
942 significance of CD4(+) CD25(+) regulatory T cells and Th17 cells in peripheral blood of
943 infants with respiratory syncytial virus bronchiolitis]. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi*
944 **28**:426-428.

- 945 52. **Bacharier LB, Coverstone A, Schweiger T, Gregory G, Yin-DeClue H, Sajol G, Giri T,**
946 **Sierra O, Atkinson J, Wilson B, Zheng J, Schechtman K, Castro M.** 2013. Regulatory T
947 cells in acute severe RSV bronchiolitis. American Journal of Respiratory and Critical Care
948 Medicine Conference: American Thoracic Society International Conference, ATS **187**.
- 949 53. **Isaacs D, Bangham CR, McMichael AJ.** 1987. Cell-mediated cytotoxic response to
950 respiratory syncytial virus in infants with bronchiolitis. Lancet **2**:769-771.
- 951 54. **Jozwik A, Habibi MS, Paras A, Zhu J, Guvenel A, Dhariwal J, Almond M, Wong EHC,**
952 **Sykes A, Maybeno M, Del Rosario J, Trujillo-Torralbo MB, Mallia P, Sidney J, Peters**
953 **B, Kon OM, Sette A, Johnston SL, Openshaw PJ, Chiu C.** 2015. RSV-specific airway
954 resident memory CD8+T cells and differential disease severity after experimental human
955 infection. Nature Communications **6**:10224.
- 956 55. **Yao S, Jiang L, Moser EK, Jewett LB, Wright J, Du J, Zhou B, Davis SD, Krupp NL,**
957 **Braciale TJ, Sun J.** 2015. Control of pathogenic effector T-cell activities in situ by PD-L1
958 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus
959 infection. Mucosal Immunol **8**:746-759.
- 960 56. **de Souza APD, de Freitas D, Fernandes KEA, da Cunha MD, Fernandes JLA, Gassen**
961 **RB, Fazolo T, Pinto LA, Scotta M, Mattiello R, Pitrez PM, Bonorino C, Stein RT.** 2016.
962 Respiratory syncytial virus induces phosphorylation of mTOR at ser2448 in CD8 T cells from
963 nasal washes of infected infants. Clinical and Experimental Immunology **183**:248-257.
- 964 57. **Tasker RC, Roe MFE, Bloxham DM, White DK, Ross-Russell RI, O'Donnell DR.** 2004.
965 The neuroendocrine stress response and severity of acute respiratory syncytial virus
966 bronchiolitis in infancy. Intensive Care Medicine **30**:2257-2262.
- 967 58. **Cherukuri A, Patton K, Gasser RA, Zuo FR, Woo J, Esser MT, Tang RS.** 2013. Adults
968 65 Years Old and Older Have Reduced Numbers of Functional Memory T Cells to
969 Respiratory Syncytial Virus Fusion Protein. Clinical and Vaccine Immunology **20**:239-247.

- 970 59. **de Bree GJ, Heidema J, van Leeuwen EMM, van Bleek GM, Jonkers RE, Jansen HM,**
971 **van Lier RAW, Out TA.** 2005. Respiratory syncytial virus-specific CD8(+) memory T cell
972 responses in elderly persons. *Journal of Infectious Diseases* **191**:1710-1718.
- 973 60. **Duncan MD, Wilkes DS.** 2005. Transplant-related immunosuppression: a review of
974 immunosuppression and pulmonary infections. *Proc Am Thorac Soc* **2**:449-455.
- 975 61. **Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, Brinch L, Brune**
976 **M, De La Camara R, Dekker A, Pauksen K, Russell N, Schwarer AP, Cordonnier C.**
977 2001. Respiratory virus infections after stem cell transplantation: a prospective study from the
978 Infectious Diseases Working Party of the European Group for Blood and Marrow
979 Transplantation. *Bone Marrow Transplant* **28**:479-484.
- 980 62. **McNamara PS, Ritson P, Selby A, Hart CA, Smyth RL.** 2003. Bronchoalveolar lavage
981 cellularity in infants with severe respiratory syncytial virus bronchiolitis. *Archives of Disease*
982 *in Childhood* **88**:922-926.
- 983 63. **Reed JL, Welliver TP, Sims GP, McKinney L, Velozo L, Avendano L, Hintz K, Luma J,**
984 **Coyle AJ, Welliver RC.** 2009. Innate Immune Signals Modulate Antiviral and Polyreactive
985 Antibody Responses during Severe Respiratory Syncytial Virus Infection. *Journal of*
986 *Infectious Diseases* **199**:1128-1138.
- 987 64. **Raes M, Peeters V, Alliet P, Gillis P, Kortleven J, Magerman K, Rummens JL.** 1997.
988 Peripheral blood T and B lymphocyte subpopulations in infants with acute respiratory
989 syncytial virus bronchiolitis. *Pediatric Allergy & Immunology* **8**:97-102.
- 990 65. **Shinoff JJ, O'Brien KL, Thumar B, Shaw JB, Reid R, Hua W, Santosham M, Karron**
991 **RA.** 2008. Young infants can develop protective levels of neutralizing antibody after
992 infection with respiratory syncytial virus. *Journal of Infectious Diseases* **198**:1007-1015.
- 993 66. **Strannegard O, Cello J, Bjarnason R, Sigurbergsson F, Sigurs N.** 1997. Association
994 between pronounced IgA response in RSV bronchiolitis and development of allergic
995 sensitization. *Pediatric Allergy & Immunology* **8**:1-6.

996 67. **McNamara PS, Fonceca AM, Howarth D, Correia JB, Slupsky JR, Trinick RE, Al**
997 **Turaiki W, Smyth RL, Flanagan BF.** 2013. Respiratory syncytial virus infection of airway
998 epithelial cells, in vivo and in vitro, supports pulmonary antibody responses by inducing
999 expression of the B cell differentiation factor BAFF. *Thorax* **68**:76-81.

1000 68. **Fonceca A, McNamara P, Howarth D, Trinick R, Alturaiki W, Smyth R, Flanagan B.**
1001 2011. Human respiratory syncytial virus infection in vivo and in vitro induces airway
1002 epithelial cell expression of the B cell differentiation factor BAFF. *Immunology* **135**:94.

1003 69. **Jensen IP, Thisted E, Glikmann G, Obel N, Kofoed PE, Sambo M, Valerius NH,**
1004 **Mordhorst CH.** 1997. Secretory IgM and IgA antibodies to respiratory syncytial virus in
1005 nasopharyngeal aspirates: a diagnostic supplement to antigen detection. *Clinical & Diagnostic*
1006 *Virology* **8**:219-226.

1007 70. **Lee FEH, Falsey AR, Halliley JL, Sanz I, Walsh EE.** 2010. Circulating Antibody-Secreting
1008 Cells during Acute Respiratory Syncytial Virus Infection in Adults. *Journal of Infectious*
1009 *Diseases* **202**:1659-1666.

1010 71. **Agius G, Dindinaud G, Biggar RJ, Peyre R, Vaillant V, Ranger S, Poupet JY, Cisse MF,**
1011 **Castets M.** 1990. An epidemic of respiratory syncytial virus in elderly people: clinical and
1012 serological findings. *Journal of Medical Virology* **30**:117-127.

1013 72. **Forster J, Maier O, Lobbert J, Kaufmehl K, Streckert HJ, Werchau H.** 1996. Prevalence
1014 of antibodies against HEp-2 cell antigen in infants and children hospitalized with respiratory
1015 syncytial virus infection. *Infection* **24**:407-411.

1016 73. **Bagga B, Cehelsky JE, Vaishnaw A, Wilkinson T, Meyers R, Harrison LM, Roddam PL,**
1017 **Walsh EE, DeVincenzo JP.** 2015. Effect of Preexisting Serum and Mucosal Antibody on
1018 Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults. *Journal*
1019 *of Infectious Diseases* **212**:1719-1725.

1020 74. **Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, de Haan CAM,**
1021 **Wrammert J, Openshaw PJM, Chiu C, Mech Severe Acute I.** 2015. Impaired Antibody-

1022 mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults
 1023 with Respiratory Syncytial Virus. American Journal of Respiratory and Critical Care
 1024 Medicine **191**:1040-1049.

1025 75. **Bagga B, Cehelsky J, Vaishnaw A, Wilkinson T, Meyers R, Harrison L, Roddam P,**
 1026 **Walsh EE, DeVincenzo JP.** 2011. Effect of serum and mucosal antibody on experimental
 1027 RSV infections of adults. Journal of Investigative Medicine **59**:487-488.

1028 76. **Hall CB, Walsh EE, Long CE, Schnabel KC.** 1991. Immunity to and frequency of
 1029 reinfection with respiratory syncytial virus. Journal of Infectious Diseases **163**:693-698.

1030 77. **Lee FEH, Walsh EE, Falsey AR, Betts RE, Treanor JJ.** 2004. Experimental infection of
 1031 humans with A2 respiratory syncytial virus. Antiviral Research **63**:191-196.

1032 78. **Walsh EE, Falsey AR.** 2004. Humoral and mucosal immunity in protection from natural
 1033 respiratory syncytial virus infection in adults. Journal of Infectious Diseases **190**:373-378.

1034 79. **Falsey AR, Walsh EE.** 1998. Relationship of serum antibody to risk of respiratory syncytial
 1035 virus infection in elderly adults. Journal of Infectious Diseases **177**:463-466.

1036 80. **Medrano Gonzalez L, Jozwik AA, Habibi MS, Openshaw PJM, Chiu C.** 2014. Quality of
 1037 antigen-specific B-cell responses as a correlate of protection against RSV. Immunology
 1038 **143**:75.

1039 81. **Tsutsumi H, Matsuda K, Yamazaki H, Ogra PL, Chiba S.** 1995. Different kinetics of
 1040 antibody responses between IgA and IgG classes in nasopharyngeal secretion in infants and
 1041 children during primary respiratory syncytial virus infection. Acta Paediatrica Japonica
 1042 **37**:464-468.

1043 82. **Freitas GRO, Silva DAO, Yokosawa J, Paula NT, Costa LF, Carneiro BM, Ribeiro**
 1044 **LZG, Oliveira TFM, Mineo JR, Queiroz DAO.** 2011. Antibody Response and Avidity of
 1045 Respiratory Syncytial Virus-Specific Total IgG, IgG1, and IgG3 in Young Children. Journal
 1046 of Medical Virology **83**:1826-1833.

1047 83. **Murphy BR, Graham BS, Prince GA, Walsh EE, Chanock RM, Karzon DT, Wright PF.**
 1048 1986. Serum and nasal-wash immunoglobulin G and A antibody response of infants and

1049 children to respiratory syncytial virus F and G glycoproteins following primary infection. J
1050 Clin Microbiol **23**:1009-1014.

1051 84. **Yamazaki H, Tsutsumi H, Matsuda K, Nagai K, Ogra PL, Chiba S.** 1994. Effect of
1052 maternal antibody on IgA antibody response in nasopharyngeal secretion in infants and
1053 children during primary respiratory syncytial virus infection. Journal of General Virology
1054 **75**:2115-2119.

1055 85. **Falsey AR, Singh HK, Walsh EE.** 2006. Serum antibody decay in adults following natural
1056 respiratory syncytial virus infection. Journal of Medical Virology **78**:1493-1497.

1057 86. **Sande CJ, Mutunga MN, Medley GF, Cane PA, Nokes DJ.** 2013. Group- and genotype-
1058 specific neutralizing antibody responses against respiratory syncytial virus in infants and
1059 young children with severe pneumonia. J Infect Dis **207**:489-492.

1060 87. **Yamazaki H, Tsutsumi H, Matsuda K, Nagai K, Ogra PL, Chiba S.** 1994. Respiratory
1061 syncytial virus group-specific antibody response in nasopharyngeal secretions from infants
1062 and children after primary infection. Clinical & Diagnostic Laboratory Immunology **1**:469-
1063 472.

1064 88. **McGill A, Greensill J, Marsh R, Craft AW, Toms GL.** 2004. Detection of human
1065 respiratory syncytial virus genotype specific antibody responses in infants. Journal of Medical
1066 Virology **74**:492-498.

1067 89. **Kaul TN, Welliver RC, Ogra PL.** 1982. Appearance of complement components and
1068 immunoglobulins on nasopharyngeal epithelial cells following naturally acquired infection
1069 with respiratory syncytial virus. J Med Virol **9**:149-158.

1070 90. **Kaul TN, Welliver RC, Faden HS, Ogra PL.** 1984. The development of respiratory
1071 syncytial virus-specific immune complexes in nasopharyngeal secretions following natural
1072 infection. J Clin Lab Immunol **15**:187-190.

1073 91. **Kaul TN, Welliver RC, Ogra PL.** 1982. Development of antibody-dependent cell-mediated
1074 cytotoxicity in the respiratory tract after natural infection with respiratory syncytial virus.
1075 Infect Immun **37**:492-498.

- 1076 92. **Russi JC, Delfraro A, Borthagaray MD, Velazquez B, Garcia-Barreno B, Hortal M.**
1077 1993. Evaluation of immunoglobulin E-specific antibodies and viral antigens in
1078 nasopharyngeal secretions of children with respiratory syncytial virus infections. *Journal of*
1079 *Clinical Microbiology* **31**:819-823.
- 1080 93. **Rabatic S, Gagro A, Lokar-Kolbas R, Krsulovic-Hresic V, Vrtar Z, Popow-Kraupp T,**
1081 **Drazenovic V, Mlinaric-Galinovic G.** 1997. Increase in CD23+ B cells in infants with
1082 bronchiolitis is accompanied by appearance of IgE and IgG4 antibodies specific for
1083 respiratory syncytial virus. *Journal of Infectious Diseases* **175**:32-37.
- 1084 94. **Welliver RC, Wong DT, Sun M, Middleton E, Jr., Vaughan RS, Ogra PL.** 1981. The
1085 development of respiratory syncytial virus-specific IgE and the release of histamine in
1086 nasopharyngeal secretions after infection. *N Engl J Med* **305**:841-846.
- 1087 95. **Chung HL, Jang YY.** 2016. High serum IgE level in the children with acute respiratory
1088 syncytial virus infection is associated with severe disease. *Journal of Allergy and Clinical*
1089 *Immunology* **137**:AB110.
- 1090 96. **Welliver RC, Duffy L.** 1993. The relationship of RSV-specific immunoglobulin E antibody
1091 responses in infancy, recurrent wheezing, and pulmonary function at age 7-8 years. *Pediatr*
1092 *Pulmonol* **15**:19-27.
- 1093 97. **Ye Q, Shao WX, Shang SQ, Pan YX, Shen HQ, Chen XJ.** 2015. Epidemiological
1094 Characteristics and Immune Status of Children With Respiratory Syncytial Virus. *Journal of*
1095 *Medical Virology* **87**:323-329.
- 1096 98. **Hattori S, Shimojo N, Mashimo T, Inoue Y, Ono Y, Kohno Y, Okamoto Y, Hata A,**
1097 **Suzuki Y.** 2011. Relationship between RANTES polymorphisms and respiratory syncytial
1098 virus bronchiolitis in a Japanese infant population. *Jpn J Infect Dis* **64**:242-245.
- 1099 99. **Fernandez JA, Roine I, Vazquez A, Caneo M.** 2005. Soluble interleukin-2 receptor
1100 (sCD25) and interleukin-10 plasma concentrations are associated with severity of primary
1101 respiratory syncytial virus (RSV) infection. *European Cytokine Network* **16**:81-90.

1102 100. **Fernandez JA, Tapia L, Palomino MA, Larranaga C, Pena M, Jaramillo H.** 2005.
1103 Plasma interferon-gamma, interleukin-10 and soluble markers of immune activation in infants
1104 with primary adenovirus (ADV) and respiratory syncytial virus (RSV) infection. *European*
1105 *Cytokine Network* **16**:35-40.

1106 101. **Chung HL, Park HJ, Kim SY, Kim SG.** 2007. Age-related difference in immune responses
1107 to respiratory syncytial virus infection in young children. *Pediatric Allergy and Immunology*
1108 **18**:94-99.

1109 102. **Bont L, Heijnen CJ, Kavelaars A, van Aalderen WMC, Brus F, Draaisma JTM, Geelen**
1110 **SM, van Vught HJ, Kimpfen JLL.** 1999. Peripheral blood cytokine responses and disease
1111 severity in respiratory syncytial virus bronchiolitis. *European Respiratory Journal* **14**:144-
1112 149.

1113 103. **Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC.** 2001. Macrophage
1114 inflammatory protein-1 alpha (not T helper type 2 cytokines) is associated with severe forms
1115 of respiratory syncytial virus bronchiolitis. *Journal of Infectious Diseases* **184**:393-399.

1116 104. **Kim CK, Callaway Z, Koh YY, Kim SH, Fujisawa T.** 2012. Airway IFN-gamma
1117 Production During RSV Bronchiolitis is Associated with Eosinophilic Inflammation. *Lung*
1118 **190**:183-188.

1119 105. **Choi J, Callaway Z, Kim HB, Fujisawa T, Kim CK.** 2010. The role of TNF-alpha in
1120 eosinophilic inflammation associated with RSV bronchiolitis. *Pediatric Allergy and*
1121 *Immunology* **21**:474-479.

1122 106. **Semple MG, Dankert HM, Ebrahimi B, Correia JB, Booth JA, Stewart JP, Smyth RL,**
1123 **Hart CA.** 2007. Severe Respiratory Syncytial Virus Bronchiolitis in Infants Is Associated
1124 with Reduced Airway Interferon Gamma and Substance P. *PLoS One* **2**:e1038.

1125 107. **Garcia C, Soriano-Fallas A, Lozano J, Leos N, Gomez AM, Ramilo O, Mejias A.** 2012.
1126 Decreased innate immune cytokine responses correlate with disease severity in children with

1127 respiratory syncytial virus and human rhinovirus bronchiolitis. *Pediatric Infectious Disease*
1128 *Journal* **31**:86-89.

1129 108. **Bennett BL, Garofalo RP, Cron SG, Hosakote YM, Atmar RL, Macias CG, Piedra PA.**
1130 2007. Immunopathogenesis of respiratory syncytial virus bronchiolitis. *J Infect Dis* **195**:1532-
1131 1540.

1132 109. **Kristjansson S, Bjarnarson SP, Wennergren G, Palsdottir AH, Arnadottir T,**
1133 **Haraldsson A, Jonsdottir I.** 2005. Respiratory syncytial virus and other respiratory viruses
1134 during the first 3 months of life promote a local T_H-like response. *Journal of*
1135 *Allergy and Clinical Immunology* **116**:805-811.

1136 110. **Bont L, Heijnen CJ, Kavelaars A, van Aalderen WMC, Brus F, Draaisma JMT,**
1137 **Pekelharing-Berghuis M, van Diemen-Steenvoorde R, Kimpen JLL.** 2001. Local
1138 interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection
1139 are associated with disease severity. *Journal of Infectious Diseases* **184**:355-358.

1140 111. **Diaz PV, Gaggero AA, Pinto RA, Mamani R, Uasapud PA, Bono MR.** 2013. Levels of
1141 inflammatory cytokines and plasma cortisol in respiratory syncytial virus bronchiolitis.
1142 *Revista Medica de Chile* **141**:574-581.

1143 112. **Giugno KM, Machado DC, Amantea SL, Menna Barreto SS.** 2004. Concentrations of
1144 interleukin-2 in the nasopharyngeal secretion of children with acute respiratory syncytial
1145 virus bronchiolitis. [Portuguese]. *Jornal de pediatria* **80**:315-320.

1146 113. **McNamara PS, Flanagan BF, Selby AM, Hart CA, Smyth RL.** 2004. Pro- and anti-
1147 inflammatory responses in respiratory syncytial virus bronchiolitis. *European Respiratory*
1148 *Journal* **23**:106-112.

1149 114. **van Benten IJ, van Drunen CM, Koevoet JLM, Koopman LP, Hop WCJ, Osterhaus A,**
1150 **Neijens HJ, Fokkens WJ.** 2005. Reduced nasal IL-10 and enhanced TNF alpha responses
1151 during rhinovirus and RSV-Induced upper respiratory tract infection in atopic and non-atopic
1152 infants. *Journal of Medical Virology* **75**:348-357.

1153 115. **Matsuda K, Tsutsumi H, Okamoto Y, Chiba C.** 1995. Development of interleukin 6 and
1154 tumor necrosis factor alpha activity in nasopharyngeal secretions of infants and children

1155 during infection with respiratory syncytial virus. Clinical & Diagnostic Laboratory
1156 Immunology **2**:322-324.

1157 116. **Hornsleth A, Klug B, Nir M, Johansen J, Hansen KS, Christensen LS, Larsen LB.** 1998.
1158 Severity of respiratory syncytial virus disease related to type and genotype of virus and to
1159 cytokine values in nasopharyngeal secretions. Pediatric Infectious Disease Journal **17**:1114-
1160 1121.

1161 117. **van Bente IJ, van Drunen CM, Koopman LP, KleinJan A, van Middelkoop BC, de**
1162 **Waal L, Osterhaus A, Neijens HJ, Fokkens WJ.** 2003. RSV-induced bronchiolitis but not
1163 upper respiratory tract infection is accompanied by an increased nasal IL-18 response. Journal
1164 of Medical Virology **71**:290-297.

1165 118. **Faber TE, Groen H, Welfing M, Jansen KJG, Bont LJ.** 2012. Specific increase in local
1166 IL-17 production during recovery from primary RSV bronchiolitis. Journal of Medical
1167 Virology **84**:1084-1088.

1168 119. **Tabarani CM, Bonville CA, Suryadevara M, Branigan P, Wang D, Huang D, Rosenberg**
1169 **HF, Domachowske JB.** 2013. Novel inflammatory markers, clinical risk factors and virus
1170 type associated with severe respiratory syncytial virus infection. Pediatr Infect Dis J **32**:e437-
1171 442.

1172 120. **Garofalo RP, Hintz KH, Hill V, Ogra PL, Welliver RC.** 2004. Production of interferon
1173 gamma in respiratory syncytial virus infection of humans is not associated with interleukins
1174 12 and 18. Journal of Medical Virology **73**:289-294.

1175 121. **Mella C, Suarez-Arrabal MC, Lopez S, Stephens J, Fernandez S, Hall MW, Ramilo O,**
1176 **Mejias A.** 2013. Innate immune dysfunction is associated with enhanced disease severity in
1177 infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis **207**:564-573.

1178 122. **Diaz PV, Pinto RA, Mamani R, Uasapud PA, Bono MR, Gaggero AA, Guerrero J,**
1179 **Goecke A.** 2012. Increased Expression of the Glucocorticoid Receptor beta in Infants With
1180 RSV Bronchiolitis. Pediatrics **130**:E804-E811.

- 1181 123. **Hassan MA, Eldin AM, Ahmed MM.** 2008. T - helper2 /T - helper1 imbalance in
1182 respiratory syncytial virus bronchiolitis in relation to disease severity and outcome. Egyptian
1183 Journal of Immunology/Egyptian Association of Immunologists **15**:153-160.
- 1184 124. **Vieira RA, Diniz EMA, Mejr C.** 2010. Concentrations of inflammatory mediators in
1185 Brazilian newborn with respiratory syncytial virus lower respiratory tract infection. Journal of
1186 Maternal-Fetal and Neonatal Medicine **23**:635-636.
- 1187 125. **Vieira RA, Diniz EM, Ceccon ME.** 2010. Correlation between inflammatory mediators in
1188 the nasopharyngeal secretion and in the serum of children with lower respiratory tract
1189 infection caused by respiratory syncytial virus and disease severity. J Bras Pneumol **36**:59-66.
- 1190 126. **Sung RYT, Hui SHL, Wong CK, Lam CWK, Yin J.** 2001. A comparison of cytokine
1191 responses in respiratory syncytial virus and influenza A infections in infants. European
1192 Journal of Pediatrics **160**:117-122.
- 1193 127. **Midulla F, Tromba V, Lo Russo L, Mileto F, Sabatino G, Sgarrella M, Panuska JR,**
1194 **Manganozzi L, Korn D, Moret C.** 2006. Cytokines in the nasal washes of children with
1195 respiratory syncytial virus bronchiolitis. International Journal of Immunopathology and
1196 Pharmacology **19**:231-235.
- 1197 128. **Chung HL, Kim WT, Kim JK, Choi EJ, Lee JH, Lee GH, Kim SG.** 2005. Relationship
1198 between atopic status and nasal interleukin 10 and 11 levels in infants with respiratory
1199 syncytial virus bronchiolitis. Annals of Allergy Asthma & Immunology **94**:267-272.
- 1200 129. **Murai H, Terada A, Mizuno M, Asai M, Hirabayashi Y, Shimizu S, Morishita T, Kakita**
1201 **H, Hussein MH, Ito T, Kato I, Asai K, Togari H.** 2007. IL-10 and RANTES are elevated in
1202 nasopharyngeal secretions of children with respiratory syncytial virus infection. Allergology
1203 International **56**:157-163.
- 1204 130. **Saravia J, You D, Shrestha B, Jalgama S, Siefker D, Lee GI, Harding JN, Jones TL,**
1205 **Rovnaghi C, Bagga B, DeVincenzo JP, Cormier SA.** 2015. Respiratory Syncytial Virus
1206 Disease Is Mediated by Age-Variable IL-33. PLoS Pathogens **11**:e1005217.

1207 131. **McNamara PS, Flanagan BF, Baldwin LM, Newland P, Hart CA, Smyth RL.** 2004.
1208 Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus
1209 bronchiolitis. *Lancet* **363**:1031-1037.

1210 132. **Sheeran P, Jafri H, Carubelli C, Saavedra J, Johnson C, Krisher K, Sanchez PJ, Ramilo**
1211 **O.** 1999. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of
1212 children with respiratory syncytial virus disease. *Pediatric Infectious Disease Journal* **18**:115-
1213 122.

1214 133. **Bertrand P, Lay MK, Piedimonte G, Brockmann PE, Palavecino CE, Hernandez J,**
1215 **Leon MA, Kalergis AM, Bueno SM.** 2015. Elevated IL-3 and IL-12p40 levels in the lower
1216 airway of infants with RSV-induced bronchiolitis correlate with recurrent wheezing. *Cytokine*
1217 **76**:417-423.

1218 134. **Hornsleth A, Loland L, Larsen LB.** 2001. Cytokines and chemokines in respiratory
1219 secretion and severity of disease in infants with respiratory syncytial virus (RSV) infection.
1220 *Journal of Clinical Virology* **21**:163-170.

1221 135. **Brandenburg AH, Kleinjan A, van't Land B, Moll HA, Timmerman HH, de Swart RL,**
1222 **Neijens HJ, Fokkens W, Osterhaus A.** 2000. Type 1-like immune response is found in
1223 children with respiratory syncytial virus infection regardless of clinical severity. *Journal of*
1224 *Medical Virology* **62**:267-277.

1225 136. **Diaz PV, Valdivia G, Gaggero AA, Bono MR, Zepeda G, Rivas M, Uasapud P, Pinto**
1226 **RA, Boza ML, Guerrero J.** 2015. Pro-Inflammatory Cytokines in Nasopharyngeal Aspirate
1227 From Hospitalized Children With Respiratory Syncytial Virus Infection With or Without
1228 Rhinovirus Bronchiolitis, and Use of the Cytokines as Predictors of Illness Severity. *Medicine*
1229 **94**:e1512.

1230 137. **Walsh EE, Peterson DR, Kalkanoglu AE, Lee FE, Falsey AR.** 2013. Viral shedding and
1231 immune responses to respiratory syncytial virus infection in older adults. *J Infect Dis*
1232 **207**:1424-1432.

- 1233 138. **DeVincenzo JP, Wilkinson T, Vaishnav A, Cehelsky J, Meyers R, Nochur S, Harrison**
1234 **L, Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme**
1235 **R, Dorsett P, Alvarez R, Lambkin-Williams R.** 2010. Viral Load Drives Disease in
1236 Humans Experimentally Infected with Respiratory Syncytial Virus. *American Journal of*
1237 *Respiratory and Critical Care Medicine* **182**:1305-1314.
- 1238 139. **Caballero MT, Serra ME, Acosta PL, Marzec J, Gibbons L, Salim M, Rodriguez A,**
1239 **Reynaldi A, Garcia A, Bado D, Buchholz UJ, Hijano DR, Coviello S, Newcomb D,**
1240 **Bellabarba M, Ferolla FM, Libster R, Berenstein A, Siniawski S, Blumetti V,**
1241 **Echavarria M, Pinto L, Lawrence A, Ossorio MF, Grosman A, Mateu CG, Bayle C,**
1242 **Dericco A, Pellegrini M, Igarza I, Repetto HA, Grimaldi LA, Gudapati P, Polack NR,**
1243 **Althabe F, Shi M, Ferrero F, Berge E, Stein RT, Peebles RS, Boothby M, Kleeberger**
1244 **SR, Polack FP.** 2015. TLR4 genotype and environmental LPS mediate RSV bronchiolitis
1245 through Th2 polarization. *Journal of Clinical Investigation* **125**:571-582.
- 1246 140. **Roe MFE, Bloxham DM, Cowburn AS, O'Donnell DR.** 2011. Changes in helper
1247 lymphocyte chemokine receptor expression and elevation of IP-10 during acute respiratory
1248 syncytial virus infection in infants. *Pediatric Allergy and Immunology* **22**:229-234.
- 1249 141. **Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO.** 2003. Type 1 and type 2
1250 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. *American Journal of*
1251 *Respiratory and Critical Care Medicine* **168**:633-639.
- 1252 142. **Chen ZM, Mao JH, Du LZ, Tang YM.** 2002. Association of cytokine responses with
1253 disease severity in infants with respiratory syncytial virus infection. *Acta Paediatrica* **91**:914-
1254 922.
- 1255 143. **Pancham K, Perez GF, Husen S, Jain A, Kurdi B, Rodriguez-Martinez CE, Preciado D,**
1256 **Rose MC, Nino G.** 2015. Premature infants have impaired airway antiviral IFN gamma
1257 responses to human metapneumovirus compared to respiratory syncytial virus. *Pediatric*
1258 *Research* **78**:389-394.

1259 144. **Mobbs KJ, Smyth RL, O'Hea U, Ashby D, Ritson P, Hart CA.** 2002. Cytokines in severe
1260 respiratory syncytial virus bronchiolitis. *Pediatric Pulmonology* **33**:449-452.

1261 145. **Looney RJ, Falsey AR, Walsh E, Campbell D.** 2002. Effect of aging on cytokine
1262 production in response to respiratory syncytial virus infection. *J Infect Dis* **185**:682-685.

1263 146. **Noah TL, Ivins SS, Murphy P, Kazachkova I, Moats-Staats B, Henderson FW.** 2002.
1264 Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus
1265 bronchiolitis. *Clinical Immunology* **104**:86-95.

1266 147. **Smyth RL, Mobbs KJ, O'Hea U, Ashby D, Hart CA.** 2002. Respiratory syncytial virus
1267 bronchiolitis: Disease severity, interleukin-8, and virus genotype. *Pediatric Pulmonology*
1268 **33**:339-346.

1269 148. **Biswas S, Friedland JS, Remick DG, Davies EG, Sharland M.** 1995. Elevated plasma
1270 interleukin 8 in respiratory syncytial virus bronchiolitis. *Pediatric Infectious Disease Journal*
1271 **14**:919.

1272 149. **Noah TL, Becker S.** 2000. Chemokines in nasal secretions of normal adults experimentally
1273 infected with respiratory syncytial virus. *Clinical Immunology* **97**:43-49.

1274 150. **Adams O, Weis J, Jasinska K, Vogel M, Tenenbaum T.** 2015. Comparison of Human
1275 Metapneumovirus, Respiratory Syncytial Virus and Rhinovirus Respiratory Tract Infections
1276 in Young Children Admitted to Hospital. *Journal of Medical Virology* **87**:275-280.

1277 151. **Assefa D, Amin N, Dozor AJ, Parton LA.** 2011. Attenuated interleukin-8/leukocyte
1278 immunoresponse in preterm infants compared with term infants hospitalized with respiratory
1279 syncytial virus bronchiolitis: a pilot study. *Human Immunology* **72**:708-711.

1280 152. **Stoppelenburg AJ, Salimi V, Hennis M, Plantinga M, in 't Veld RH, Walk J, Meerding**
1281 **J, Coenjaerts F, Bont L, Boes M.** 2013. Local IL-17A Potentiates Early Neutrophil
1282 Recruitment to the Respiratory Tract during Severe RSV Infection. *PLoS One* **8**:e78461.

- 1283 153. **McNamara PS, Flanagan BF, Hart CA, Smyth RL.** 2005. Production of chemokines in the
1284 lungs of infants with severe respiratory syncytial virus bronchiolitis. *Journal of Infectious*
1285 *Diseases* **191**:1225-1232.
- 1286 154. **Becker S, Reed W, Henderson FW, Noah TL.** 1997. RSV infection of human airway
1287 epithelial cells causes production of the beta-chemokine RANTES. *American Journal of*
1288 *Physiology* **272**:L512-520.
- 1289 155. **Garofalo RP, Olszewska-Pazdrak B, Ogra PL, Welliver RC.** 2001. Beta-chemokines in
1290 nasal secretions of infants with respiratory syncytial virus-induced respiratory infections.
1291 *Pediatric Asthma, Allergy and Immunology* **15**:89-96.
- 1292 156. **Garofalo RP, Hintz KH, Hill V, Patti J, Ogra PL, Welliver RC.** 2005. A comparison of
1293 epidemiologic and immunologic features of bronchiolitis caused by influenza virus and
1294 respiratory syncytial virus. *Journal of Medical Virology* **75**:282-289.
- 1295 157. **Scagnolari C, Midulla F, Pierangeli A, Moretti C, Bonci E, Berardi R, De Angelis D,**
1296 **Selvaggi C, Di Marco P, Girardi E, Antonelli G.** 2009. Gene Expression of Nucleic Acid-
1297 Sensing Pattern Recognition Receptors in Children Hospitalized for Respiratory Syncytial
1298 Virus-Associated Acute Bronchiolitis. *Clinical and Vaccine Immunology* **16**:816-823.
- 1299 158. **Nakayama T, Sonoda S, Urano T, Sasaki K, Maehara N, Makino S.** 1993. Detection of
1300 alpha-interferon in nasopharyngeal secretions and sera in children infected with respiratory
1301 syncytial virus. *Pediatric Infectious Disease Journal* **12**:925-929.
- 1302 159. **Selvaggi C, Pierangeli A, Fabiani M, Spano L, Nicolai A, Papoff P, Moretti C, Midulla**
1303 **F, Antonelli G, Scagnolari C.** 2014. Interferon lambda 1-3 expression in infants hospitalized
1304 for RSV or HRV associated bronchiolitis. *Journal of Infection* **68**:467-477.
- 1305 160. **Nenna R, Ferrara M, Nicolai A, Pierangeli A, Scagnolari C, Papoff P, Antonelli G,**
1306 **Moretti C, Midulla F.** 2015. Viral Load in Infants Hospitalized for Respiratory Syncytial
1307 Virus Bronchiolitis Correlates with Recurrent Wheezing at Thirty-Six-Month Follow-Up.
1308 *Pediatr Infect Dis J* **34**:1131-1132.

1309 161. **Sun Y, Jain D, Koziol-White CJ, Genoyer E, Gilbert M, Tapia K, Panettieri RA,**
1310 **Hodinka RL, Lopez CB.** 2015. Immunostimulatory Defective Viral Genomes from
1311 Respiratory Syncytial Virus Promote a Strong Innate Antiviral Response during Infection in
1312 Mice and Humans. *PLoS Pathogens* **11**:e1005122.

1313 162. **Inchley CS, Sonerud T, Fjaerli HO, Nakstad B.** 2015. Nasal mucosal microRNA
1314 expression in children with respiratory syncytial virus infection. *BMC Infectious Diseases*
1315 **15**:150.

1316 163. **Liu S, Gao L, Wang X, Xing Y.** 2015. Respiratory syncytial virus infection inhibits TLR4
1317 signaling via up-regulation of miR-26b. *Cell Biology International* **39**:1376-1383.

1318 164. **Mejias A, Dimo B, Suarez NM, Garcia C, Suarez-Arrabal MC, Jartti T, Blankenship D,**
1319 **Jordan-Villegas A, Ardura MI, Xu ZH, Banchereau J, Chaussabel D, Ramilo O.** 2013.
1320 Whole Blood Gene Expression Profiles to Assess Pathogenesis and Disease Severity in
1321 Infants with Respiratory Syncytial Virus Infection. *PLoS Medicine* **10**:e1001549.

1322 165. **Bucasas KL, Mian AI, Demmler-Harrison GJ, Caviness AC, Piedra PA, Franco LM,**
1323 **Shaw CA, Zhai YJ, Wang XQ, Bray MS, Couch RB, Belmont JW.** 2013. Global Gene
1324 Expression Profiling in Infants With Acute Respiratory Syncytial Virus Bronchiolitis
1325 Demonstrates Systemic Activation of Interferon Signaling Networks. *Pediatric Infectious*
1326 *Disease Journal* **32**:E68-E76.

1327 166. **Fjaerli HO, Bukholm G, Krog A, Skjaeret C, Holden M, Nakstad B.** 2006. Whole blood
1328 gene expression in infants with respiratory syncytial virus bronchiolitis. *BMC Infectious*
1329 *Diseases* **6**:175.

1330 167. **van den Kieboom CH, Ahout IML, Zomer A, Brand KH, de Groot R, Ferwerda G, de**
1331 **Jonge MI.** 2015. Nasopharyngeal gene expression, a novel approach to study the course of
1332 respiratory syncytial virus infection. *European Respiratory Journal* **45**:718-725.

1333 168. **Seed PC.** 2016. Do Bacteria in the Gut Set the Stage for Who Gets Viral Bronchiolitis and Its
1334 Severity? *Pediatrics* **138**:e20161377.

- 1335 169. **Prevaes SM, de Winter-de Groot KM, Janssens HM, de Steenhuijsen Piters WA,**
1336 **Tramper-Stranders GA, Wyllie AL, Hasrat R, Tiddens HA, van Westreenen M, van der**
1337 **Ent CK, Sanders EA, Bogaert D.** 2016. Development of the Nasopharyngeal Microbiota in
1338 Infants with Cystic Fibrosis. *Am J Respir Crit Care Med* **193**:504-515.
- 1339 170. **de Steenhuijsen Piters WA, Heinonen S, Hasrat R, Bunsow E, Smith B, Suarez-Arrabal**
1340 **MC, Chaussabel D, Cohen DM, Sanders EA, Ramilo O, Bogaert D, Mejias A.** 2016.
1341 Nasopharyngeal Microbiota, Host Transcriptome, and Disease Severity in Children with
1342 Respiratory Syncytial Virus Infection. *Am J Respir Crit Care Med* **194**:1104-1115.
- 1343 171. **Zomer-Kooijker K, van der Ent CK, Ermers MJ, Uiterwaal CS, Rovers MM, Bont LJ.**
1344 2014. Increased risk of wheeze and decreased lung function after respiratory syncytial virus
1345 infection. *PLoS One* **9**:e87162.
- 1346 172. **Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL,**
1347 **Bont L.** 2013. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. *N*
1348 *Engl J Med* **368**:1791-1799.
- 1349 173. **Pino M, Kelvin DJ, Bermejo-Martin JF, Alonso A, Matias V, Tenorio A, Rico L, Eiros**
1350 **JM, Castrodeza J, Blanco-Quiros A, Ardura J, de Lejarazu RO.** 2009. Nasopharyngeal
1351 aspirate cytokine levels 1 yr after severe respiratory syncytial virus infection. *Pediatric*
1352 *Allergy and Immunology* **20**:791-795.
- 1353 174. **Kitcharoensakkul M, Bacharier LB, Yin-Declue H, Schweiger T, Goss CW, Boomer JS,**
1354 **Sajol G, Schechtman K, Castro M.** 2016. Increased nasal plasmacytoid dendritic cells are
1355 associated with recurrent wheezing following severe RSV bronchiolitis. *Journal of Allergy*
1356 *and Clinical Immunology* **137**:AB411.
- 1357 175. **Borchers AT, Chang C, Gershwin ME, Gershwin LJ.** 2013. Respiratory syncytial virus--a
1358 comprehensive review. *Clin Rev Allergy Immunol* **45**:331-379.

- 1359 176. **Knudson CJ, Hartwig SM, Meyerholz DK, Varga SM.** 2015. RSV vaccine-enhanced
1360 disease is orchestrated by the combined actions of distinct CD4 T cell subsets. *PLoS Pathog*
1361 **11:e1004757.**
- 1362 177. **Currie SM, Findlay EG, McFarlane AJ, Fitch PM, Bottcher B, Colegrave N,**
1363 **Paras A, Jozwik A, Chiu C, Schwarze J, Davidson DJ.** 2016. Cathelicidins Have
1364 Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective
1365 Function In Vivo in Mice and Humans. *Journal of Immunology* **196**:2699-2710.
- 1366 178. **Kerr MH, Paton JY.** 1999. Surfactant protein levels in severe respiratory syncytial
1367 virus infection. *Am J Respir Crit Care Med* **159**:1115-1118.
- 1368 179. **Dargaville PA, South M, McDougall PN.** 1996. Surfactant abnormalities in infants
1369 with severe viral bronchiolitis. *Arch Dis Child* **75**:133-136.
- 1370 180. **Skelton R, Holland P, Darowski M, Chetcuti PA, Morgan LW, Harwood JL.**
1371 1999. Abnormal surfactant composition and activity in severe bronchiolitis. *Acta*
1372 *Paediatr* **88**:942-946.
- 1373 181. **Wang SZ, Doyle IR, Nicholas TE, Forsyth KD.** 1999. Plasma surfactant protein-B
1374 is elevated in infants with respiratory syncytial virus-induced bronchiolitis. *Pediatr*
1375 *Res* **46**:731-734.
- 1376 182. **Kong MY, Clancy JP, Peng N, Li Y, Szul TJ, Xu X, Oster R, Sullender W,**
1377 **Ambalavanan N, Blalock JE, Gaggar A.** 2014. Pulmonary matrix
1378 metalloproteinase-9 activity in mechanically ventilated children with respiratory
1379 syncytial virus. *Eur Respir J* **43**:1086-1096.
- 1380 183. **Kong M, Peng N, Jackson P, Clancy J, Blalock E, Gaggar A.** 2012. 174:
1381 dysregulated matrix metalloproteinase-9 activity and elevated proline-glycine-proline

1382 (pgp) levels are observed in pediatric rsv-induced lung injury. Critical Care Medicine
1383 **40**:1-328.

1384 184. **Schuurhof A, Bont L, Hodemaekers HM, de Klerk A, de Groot H, Hofland RW,**
1385 **van de Pol AC, Kimpfen JL, Janssen R.** 2012. Proteins involved in extracellular
1386 matrix dynamics are associated with respiratory syncytial virus disease severity. Eur
1387 Respir J **39**:1475-1481.

1388 185. **Kawasaki Y, Aoyagi Y, Abe Y, Go H, Imamura T, Kaneko M, Ito M, Katayose**
1389 **M, Hashimoto K, Hosoya M.** 2009. Serum KL-6 levels as a biomarker of lung injury
1390 in respiratory syncytial virus bronchiolitis. J Med Virol **81**:2104-2108.

1391 186. **Bem RA, Bos AP, Wosten-van Asperen RM, Bruijn M, Lutter R, Sprick MR,**
1392 **van Woensel JB.** 2010. Potential role of soluble TRAIL in epithelial injury in
1393 children with severe RSV infection. Am J Respir Cell Mol Biol **42**:697-705.

1394 **AUTHOR BIOGRAPHIES**

1395

1396 **Dr. Clark D. Russell**

1397

1398 Clark is a medical trainee in the Regional Infectious Diseases Unit in Edinburgh, Scotland
1399 and an honorary clinical fellow of the University of Edinburgh.

1400

1401 Clark's undergraduate medical training was in Edinburgh with an elective in Vancouver in
1402 infectious diseases and microbiology. He graduated from the University of Edinburgh with a
1403 BMedSci in Infectious Diseases in 2010 then MBChB with honours in 2013 and completed
1404 the MRCP (UK) diploma in 2016. He is interested in academic infection medicine and his
1405 research experience includes molecular diagnostics, bacterial pathogenesis, host genetics and
1406 descriptive clinical studies.

1407

1408 **Dr. Stefan Unger**

1409

1410 Dr. Stefan Unger is a clinical lecturer at the Department of Child Life and Health at the
1411 University of Edinburgh and a pediatrician specialised in respiratory and sleep medicine.

1412

1413 Originally from Germany Dr. Unger qualified in medicine at the University of Edinburgh and
1414 trained in paediatrics in Scotland. Dr. Unger conducted an RCT of nutritional supplements in
1415 acutely unwell children in rural West Africa during his Medical Research Council (MRC)
1416 Career Development Fellowship studying the effect on infectious disease presentations with a
1417 focus on respiratory disease. After completion of his PhD with the London School of
1418 Hygiene and Tropical Medicine (LSHTM) he specialised in pediatric respiratory medicine
1419 with an interest in improving clinical management of bronchiolitis. As a clinical lecturer at
1420 the University of Edinburgh his research focuses on the relationship between under-nutrition
1421 and immune modulation in lower respiratory tract infections in infancy and subsequent
1422 respiratory health in high- and low-income settings.

1423

1424 **Mr. Marc Walton**

1425

1426 Marc Walton is an undergraduate student at the University of Edinburgh who recently
1427 completed the second year of his medical degree (MBChB). He is currently undertaking a
1428 one year 'intercalated' degree in neuroscience (Honours) after which he will return to clinical
1429 training to complete his medical degree. Marc started working on this systematic review
1430 whilst undertaking a period of laboratory work in Professor Jürgen Schwarze's group. His

main research interests lie in neuroscience and paediatrics and he is currently involved in projects relating to the use of outcome measures in intellectual disability; the design of neural implants; and the neuropathology of Alzheimer's disease.

Prof. Jürgen Schwarze

Dr Jürgen Schwarze is the Edward Clark Chair of Child Life and Health at the University of Edinburgh. He is an internationally recognised expert in immune mechanisms of RSV-bronchiolitis and associated airway allergy and a paediatrician specialised in allergy and respiratory medicine.

After qualifying in medicine from Freiburg University, Germany, and training in paediatrics, Dr Schwarze started to work on immune responses in RSV-bronchiolitis and allergic airway disease as a post-doctoral fellow at National Jewish Medical and Research Centre in Denver, Colorado. He then continued his research in this field at Ruhr-University Bochum (Germany) and as a Wellcome Trust Senior Clinical Fellow at Imperial College London. In 2007 he moved to the MRC-Centre for Inflammation Research at the University of Edinburgh. Dr Schwarze's research focuses on the interface between innate (lung epithelial cells, dendritic cells) and adaptive immunity in RSV-infection and subsequent reactive airway disease.

FIGURE LEGENDS

Figure 1: Mechanisms of RSV T-cell interference as a potential immune evasion strategy

RSV infection is associated with an initial systemic T-cell lymphopenia that is quantitatively associated with disease severity. RSV may interfere with T-cell responses by (A) inducing apoptosis (CD4⁺ and CD8⁺ T-cells), (B) inducing increased expression of the programmed cell death 1 (PD-1) protein which is inhibitory to activated T-cells (CD8⁺ T-cells) and (C) promoting activation of the mammalian target of rapamycin (mTOR) pathway, thus preventing memory CD8⁺ T-cell formation.

Figure 2: Summary of the human immune response to RSV and potential novel therapeutic targets

The role of major cell types (neutrophils, dendritic cells, macrophages, CD8⁺ T-cells and B-cells) is summarised, in addition to key antibody, cytokine, chemokine and other immune molecule responses. Major transcriptional changes (in peripheral blood) of immune-related pathways are shown. The deleterious role of neutrophilic inflammation and protective role of CD8⁺ T-cell mediated viral clearance is emphasised. Finally, we highlight areas where novel therapeutic interventions could potentially modulate the immune response in favour of the host.

↑ indicates immune cell recruitment to the respiratory tract

*associated with increased disease severity

1475

Table 1: Chemokines, cytokines and other immune molecules involved in the human immune response to RSV infection

Immune molecule	Respiratory tract ^a		Systemic	Additional comments	Ref ^b
	Nasal mucosa	Lung			
Th1 cytokines					
IFN- γ	+	+	+	Protective	
IL-12	+	+	+	Protective	
IL-1 α & IL-1 β	+		+	Deleterious	
IL-2	+	+	+	No association reported with severity	
TNF- α	+	+	+	Deleterious	
IL-18	+			Protective	
sCD25			+	Deleterious	
Th2 cytokines					
IL-4	+	+	+	Deleterious	
IL-6	+	+	+	Variable association with severity: see text	
IL-9	+	+		No association reported with severity	
IL-10	+	+	+	Variable association with severity: see text	
IL-13	+	+	+	No association reported with severity	
Other cytokines					
IL-8	+	+	+	Deleterious: neutrophil chemoattractant	
IL-17A	+	+		Variable association with severity: see text	
IL-33	+			No association reported with severity	130
Chemokines					
CCL-2 (MCP-1)	+	+		Deleterious	
CCL-3 (MIP-1 α)	+	+		Deleterious	
CCL-4 (MIP-1 β)	+			Variable association with severity: see text	
CCL-5 (RANTES)	+	+		Protective	
CXCL-10 (IP-10)	+		+	Deleterious	
Eotaxin	+	+		Deleterious	
Other					
IFN- λ	+			Deleterious despite stimulating ISG expression	159, 160
IFN- α	+		+	No association reported with severity	158
G-CSF	+		+	Circulating G-CSF levels are higher in infants with RSV-LRTI requiring ventilation	18, 105
Soluble ICAM-1	+		+	sICAM-1 levels in nasal fluid positively correlate with severity	40, 124, 126
Substance P	+	+		Lower concentrations associated with increased severity	106
MBL			–	No association reported with severity	44
Cathelicidin LL-37	+			Protective: in human experimental infection, higher constitutive nasal cathelicidin LL-37 is associated with reduced development of infection	177
Olfactomedin 4			+	Greater PBMC <i>Olfactomedin 4</i> gene expression was associated with need for ventilation in RSV-LRTI	19
Surfactant A, B, D		–	+	The pulmonary level of surfactant A and measurable surfactant activity increases during recovery.	178-181
MMP-9, MMP-3, PGP		+		Elevated pulmonary levels in ventilated infants are associated with hypoxia and acute lung injury	182-184
KL-6			+	Circulating KL-6 is greater in infants with RSV-LRTI requiring ventilation	185
sTRAIL		+		No association reported with severity	186

Key. +: increased production; –: reduced production

^a'Nasal mucosa' refers to measurements made in nasal fluid or nasopharyngeal aspirate; 'Lung' refers to measurements made in bronchoalveolar lavage or tracheal aspirate.


^bReferences are provided for molecules not discussed in detail in the main text.

Abbreviations used in table. CCL: C-C motif chemokine ligand; CXCL: C-X-C motif chemokine ligand; G-CSF: granulocyte colony stimulating factor; ICAM: intercellular adhesion molecule; IFN: interferon; IL: interleukin; IP-10: IFN- γ inducible protein-10; ISG: interferon stimulated gene; MBL: mannose binding lectin; MCP-1: monocyte chemoattractant protein-1; MIP: macrophage inflammatory protein; MMP: matrix metalloproteinase; PGP: proline-glycine-proline (the product of MMP hydrolysis of collagen); RANTES: regulated on activation, normal T expressed and secreted; sTRAIL: soluble TNF-related apoptosis-inducing ligand; TIMP: tissue inhibitor of metalloproteinase; TNF: tumour necrosis factor.

Possible RSV immune evasion strategies

A

CD8⁺ and
CD4⁺ T-cells




Apoptosis



T-cell lymphopenia

B

CD8⁺ T-cell




Inhibition of
activated T-cells

C


↑ Activation of
mTOR pathway



↓ Differentiation of
memory CD8⁺ T-cells



Memory CD8⁺ T-cell



Global transcriptional response (peripheral blood)	
Regulation	Pathways
↑	Neutrophil functioning Type 1 IFN signalling IFN-stimulated genes Dendritic cell maturation
↓	NK cell functioning B-cell and T-cell responses HLA-I and HLA-II